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Abstract 
 
The development of a self-tolerant and effective T cell receptor repertoire is 
dependent on interactions coordinated by various antigen presenting cells (APC) within 
the thymus. T cell receptor–self-peptide–MHC interactions are essential for determining 
T cell fate, where high affinity interactions can result in clonal deletion or regulatory T 
(Treg) cell differentiation of potentially autoreactive T cells. The APCs that provide these 
signals have distinct localization, different antigen processing features, and can provide 
different co-stimulatory signals that are also critical to these selection processes and 
may distinguish the ultimate fate of a T cell. Clonal deletion and Treg differentation of T 
cells specific for self-antigens in the thymus have been widely studied, primarily by 
approaches that focus on a single receptor (using TCR transgenes) or a single 
specificity (using pMHC tetramers). However, little is known about how distinct APCs 
coordinate clonal deletion and Treg cell development at the population level. 
Here, we report an assay that measures cleaved caspase 3 to define clonal 
deletion at the population level. This assay distinguishes clonal deletion from apoptotic 
events caused by neglect and approximates the anatomic site of deletion using CCR7. 
This approach showed that 78% of clonal deletion events occur in the cortex in mice. 
Medullary deletion events were detected at both the semi-mature and mature 
developmental stages, although mature events were associated with failed Treg cell 
induction. Using this assay, we showed that bone marrow derived APC drive 
approximately half of deletion events at both stages. We also found that both cortical 
and medullary deletion rely heavily on CD28 co-stimulation. 
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We further assessed the contribution of distinct APC subsets to clonal deletion 
and Treg cell selection using cell type ablation or deficiency. We found that total deletion 
and nascent Treg cell events were not altered in the absence of B cells, pDC, or XCR1+ 
cDC1. In an effort to eliminate SIRPa+ cDC2, we discovered that a fraction of thymic 
SIRPa+ cDC2 express the lectin CD301b. These cells resemble the type 2 immune 
response-promoting CD301b+ DC that are present in skin draining LN. CD301b 
expression was localized primarily within the thymus medulla and depended on IL-4R. 
Deficiency of these IL-4 and IL-13 signaled cDC2 caused a measurable reduction in 
clonal deletion events, suggesting a non-redundant role for tolerance induction. 
These findings demonstrate useful strategies for studying clonal deletion and 
nascent Treg cell development within the polyclonal population. Additionally, they 
provide valuable insight into how and when thymocytes undergo clonal deletion as they 
traverse through the thymus and interact with distinct APC during development. 
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Chapter 1 
 
 Introduction 
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1.1 Thymocyte selection 
Random rearrangement of the T cell receptor (TCR) α and β genes in the thymus 
enables the T cell repertoire to broadly react to a universe of potential antigens derived 
from pathogens. However, many TCRs will not be able to bind to those antigens when 
presented by the host’s limited set of major histocompatibility complex (MHC) molecules. 
Thus, a positive selection step that ensures that TCRs recognize antigens in the context 
of the host’s own MHC molecules is needed to guarantee that T cells are well equipped 
to respond when these pathogens are encountered. In addition, the ability to distinguish 
self-peptides from foreign peptides is essential to prevent the pathogenesis of 
autoimmune disease. Therefore, as T cells develop in the thymus, tolerance to self-
peptides is acquired, in which autoreactive clones are pruned from the repertoire (clonal 
deletion) or directed to a regulatory lineage (Treg differentiation).  
Antigen presenting cells (APC) orchestrate these selection events in the thymus. 
The strength of the interaction between the TCR and the self-peptide–MHC complexes 
presented by thymic APCs is crucial in determining the fate of a T cell. Weak interactions 
facilitated by cortical thymic epithelial cells (cTEC) promote positive selection, whereas 
stronger interactions drive both clonal deletion and Treg differentiation. But in addition to 
the strength of the TCR interaction, the specific peptides presented and the 
cytokine/costimulatory context of that recognition plays a critical role in the outcome of 
selection. Here, we discuss the diverse thymic APCs and how they facilitate the 
generation of a safe and effective T cell repertoire. 
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1.2 Cortical Thymic Epithelial Cells 
Double positive CD4+CD8+ (DP) thymocytes first express a surface αβ TCR in 
the cortex of the thymus. Weak TCR interactions with peptide-MHC complexes in this 
environment mediate positive selection and CD4 and CD8 lineage commitment (1). 
Cortical thymic epithelial cells (cTEC) play an essential role in this process (Figure 1.1). 
In fact, cTECs are uniquely primed to drive positive selection, in part due to their ability 
to process and present antigens via machinery distinct from other antigen presenting 
cells. 
1.2.1 Cortical Thymic Epithelial Cells and Antigen Processing 
Proteasomes degrade cytosolic proteins, resulting in peptide fragments that can 
be loaded onto MHC I molecules in the endoplasmic reticulum (ER). The catalytic core 
of the proteasome includes the three β-subunits: β1, β2, and β5 (2). While other cell 
types express either the β5- or β5i- subunits, cTECs have a specialized proteasome 
subunit that is critical for positive selection: β5t (3, 4). The ‘thymoproteasome’, unique to 
cTECs, is specifically composed of β1i (Psmb9), β2i (Psmb10), and β5t (Psmb11) 
subunits. Mice that lack b5t, and therefore, the thymoproteasome, have a substantial 
defect in positive selection of CD8 T cells (3). The number of CD8 T cells in b5t deficient 
mice is approximately 20% that of their wild type counterparts (5, 6). In addition, the 
ensuing T cell pool has diminished responsiveness to infection, demonstrating that the 
thymoproteasome is critical for shaping the T cell repertoire (5, 6). 
Since the proteasome plays a key role in producing peptides that are loaded onto 
MHC I molecules, it is reasonable to hypothesize that the β5t-containing 
thymoproteasomes may have proteolytic capabilities that lead to a unique peptide–MHC 
repertoire. Indeed, β5t promotes decreased chymotrypsin-like activity compared to 
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proteasomes that use either β5 or β5i (3). Therefore, it was hypothesized that β5t-
containing thymoproteasomes would produce peptides that are enriched for basic 
residues at the C-terminus. Since a substantial portion of the binding energy of MHC to 
peptides is through the hydrophobic C-terminus of the peptide, the thymoproteasome 
could generate peptides that bind to MHC molecules more weakly. However, it has been 
recently shown that while the thymoproteasome does produce unique peptides 
compared to the β5i-containing immunoproteasome; both generate peptides with 
hydrophobic residues at the C-terminus (7). 
The question then becomes whether cTECs promote positive selection merely 
because their peptides are different from those presented by other APCs during negative 
selection, or if the cTEC-exclusive peptides themselves are somehow specialized for 
inducing positive selection. Experimental results are mixed. When both the 
immunoproteasome and thymoproteasome subunits were removed, leaving just the 
constitutive proteasome in all thymic APCs, only 10% of mature CD8+ thymocytes 
developed (8). This decrease in CD8 T cells was rescued in Bim-deficient mice, 
suggesting that negative selection was responsible for the death of most CD8+ 
thymocytes (8). The authors concluded that the peptidome therefore needs to be distinct 
between cTEC and other thymic APC in order to generate a normal sized repertoire, and 
the role of β5t is to generate a distinct peptidome in cTEC. However, in another study, 
mice were engineered to express different peptidomes in cTEC versus other thymic 
APC, but without using β5t. In these mice, positive selection of CD8 T cells was still 
diminished (9), suggesting that the β5t generated peptidome is specialized for inducing 
positive selection. It is possible that both concepts are accurate, that thymoproteasome-
dependent peptides are both distinct from other thymic APC and specialized for positive 
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selection. Although the mechanism of this specialization is unclear, it may relate to 
preferentially producing low-affinity TCR ligands (7).  
Another interesting possibility that has not yet been explored experimentally is 
that the thymoproteasome may change the extent to which the peptide repertoire 
consists of “spliced peptides.” CD8 T cells have been shown to recognize peptides 
formed from two noncontiguous fragments of a protein that have been spliced together 
(10). This splicing is proteasome dependent; for example an immunoproteasome is not 
always capable of generating the same spliced peptide as a constitutive proteasome 
(11). It was recently suggested that in humans, approximately one-third of the peptides 
presented by HLA I molecules may be spliced peptides (12), indicating that this subset is 
a non-trivial proportion of the overall peptide repertoire. As the catalytic mechanism 
proposed in peptide splicing includes the function of the β-subunit of the proteasome 
(11), this leads to the appealing question of whether cTECs present unique spliced 
peptides that somehow facilitate positive selection of an even more diverse T cell 
repertoire. 
In an analogous fashion to the thymoproteasome, genes involved in the 
proteolysis of endosomal proteins are preferentially expressed in cTECs and play a role 
in the selection of the CD4 T cell repertoire. These include the thymus specific serine 
protease (TSSP) (Prss16), and cathepsin L (CatL) (13, 14). As MHC II molecules bind to 
peptides from the endosomal pathway, the function of these genes appears to be to 
create unique peptides optimized for selecting the CD4 T cell repertoire. Indeed, 
deficiency in TSSP and CatL impact positive selection of CD4 T cells (13–15). 
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1.2.2 Cortical Thymic Epithelial Cells and Antigen Presentation 
Particularly for MHC II molecules, cTEC utilize a distinct antigen presentation 
pathway in addition to unique antigen processing machinery. CD83 is a member of the 
immunoglobulin superfamily that is expressed by activated dendritic cells and a wide 
array of other cell types, including B and T cells (16). In dendritic cells, CD83 stabilizes 
MHC II by preventing ubiquitination and subsequent internalization (17). Importantly, 
CD83 is constitutively expressed in cTEC and has recently been suggested as a direct 
target of Foxn1, the lineage defining transcription factor required for thymic epithelial cell 
growth and differentiation (18). 
Mice deficient in CD83 have a substantial defect in CD4 T cell selection (19–21). 
Because selection of TCR transgenic CD4 T cells was markedly reduced in CD83-
deficient bone marrow recipients, this defect in CD4 T cell selection is likely attributed to 
a failure of positive selection, rather than disproportionate clonal deletion (19). CD83-
deficient mice have increased turnover of MHC II at cTEC cell surfaces, suggesting that, 
like in other APCs, CD83 regulates the stability of MHC II on the surface of cTECs (19, 
20). CD83 does so by antagonizing the ubiquitination-dependent lysosomal degradation 
of MHC II, which is mediated by the ubiquitin ligase, March 8 (19, 22). This mechanism 
parallels that of MHC II ubiquitination mediated by March 1 in dendritic cells (17). The 
requirement for stable MHC II surface expression for CD4 T cell selection supports the 
notion that CD4 T cells may require prolonged interactions with selecting peptides for 
positive selection, based on the kinetic signaling model for T cell lineage commitment 
(23, 24). 
It is unclear whether March 8 and March 1 evolved simultaneously in distinct cell 
types to mediate identical functions, or if March 8 plays a more specific role specialized 
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for cTEC-mediated positive selection. However, March 8 expression does not appear to 
have a direct impact on the CD4 T cell receptor repertoire (22). One separate function 
may lie in the ability to target distinct additional substrates, including CD86, which is 
targeted by March 1 in dendritic cells, but not by March 8 in thymic epithelial cells (17, 
22).  
Interestingly, Foxn1 controls the expression of both Cd83 and Psmb11, 
suggesting that Foxn1 may direct positive selection of both CD4 single positive (SP) and 
CD8SP thymocytes (18, 25). For both MHC I and MHC II restricted thymocytes, positive 
selection triggers the upregulation of C-C chemokine receptors CCR4 and CCR7 that 
guide the cells toward the medulla and its dendritic cell (DC)-rich environment (26–31). 
The APCs here have distinct roles in both clonal deletion and further differentiation of T 
cells with homeostatic functions. 
 
1.3 Medullary Thymic Epithelial Cells 
Medullary thymic epithelial cells (mTEC) play a critical role in mediating tolerance 
to self- antigens through ectopic expression of tissue restricted antigens (TRAs) (Figure 
1.1). TRA expression by mTECs largely depends on AIRE (autoimmune regulator), a 
transcriptional regulator that controls the expression of antigens normally expressed in 
certain peripheral tissues (32). Additionally, AIRE plays a role in mTEC development, 
promoting the expression of CD80 and MHC II on mature mTECs (33, 34). Lineage 
tracing experiments have revealed that mTECs undergo discrete stages of development, 
eventually downregulating AIRE. These “post-AIRE” mTECs lose their mature 
phenotype and express decreased MHC II, CD80/86, and AIRE-dependent TRAs (35, 
36). Furthermore, post-AIRE mTECs preferentially migrate toward the center of the 
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medulla, indicating that localization may dictate how mTECs facilitate central tolerance 
(35).  
Recently, an additional transcription factor that promotes thymic expression of a 
subset of TRAs via an AIRE-independent mechanism was identified. Fezf2 plays an 
essential role in mediating immune tolerance to tissue restricted antigens (37). Distinct 
pathways regulate the expression of Fezf2 and AIRE; Fezf2 is regulated by the 
lymphotoxin beta receptor (LTβR), whereas AIRE is regulated by receptor activator of 
nuclear factor-κB (RANK) and CD40, which are members of the tumor necrosis factor 
receptor superfamily (TNFRSF) (37). Therefore, Fezf2 and AIRE may have emerged at 
different points in evolution and possibly cooperate by regulating distinct gene sets. 
In addition to self-antigen presentation mediated by AIRE and Fezf2, mTECs 
produce AIRE-independent chemokine ligands, CCL19 and CCL21, which attract CCR7-
expressing developing thymocytes to the medulla (29, 31, 38). These ligands may 
facilitate interactions between these developing thymocytes and mTECs– reviewed in 
reference 39 – to drive thymocyte selection (39).  
1.3.1 Medullary Thymic Epithelial Cells and Clonal Deletion 
Classic studies showed that mTECs can facilitate tolerance by inducing clonal 
deletion of TRA-reactive T cells. In a model in which membrane-bound ovalbumin 
expression was driven by the rat insulin promoter (RIP-mOVA), and thus specifically 
expressed in an AIRE-dependent manner, AIRE knockout (KO) and mTEC-depleted 
mice had a small but significant increase in the number of OT-II transgenic CD4SP 
thymocytes, suggesting that AIRE plays a role in mediating clonal deletion (40, 41). 
More recently Malhotra et al. used tetramer enrichment to show that rare polyclonal T 
cells specific for TRA were also modestly increased in AIRE KO mice (42). Clonal 
  9 
deletion is now assumed to be the mechanism for eliminating a large number of TRA-
specific clones as mTEC ablation leads to an increase in the proportion of polyclonal 
CD4SP thymocytes (35). The role of Fezf2 in mediating clonal deletion is less clear. 
Fezf2 deficient animals do not have a difference in the CD4SP or CD8SP pool size 
compared to wild type animals, however differences in TCRVβ usage indicate Fezf2 
shapes the CD4 and CD8 TCR repertoire (37).  
Because direct MHC II-dependent interactions between thymocytes and mTECs 
are required for proper medullary architecture and organization (43), assessing the role 
of mTEC MHC II molecules in tolerance required the development of a method in which 
the class II transactivator (C2TA) was specifically knocked down (kd) in mTECs via AIRE 
promoter driven shRNA (44). C2TAkd bone marrow recipients showed a moderate 
increase in the frequency of CD4SP thymocytes, indicating that mTECs mediate clonal 
deletion. Interestingly, CD4SP thymocytes further increased when donor bone marrow 
was also deficient in MHC II, suggesting that mTECs and DCs play non-redundant roles 
in mediating deletion of the polyclonal T cell repertoire (44). A different group performed 
high throughput analysis of the TCR repertoire in animals lacking MHC II on bone 
marrow APCs or in C2TAkd animals. Repertoire analysis revealed fewer unique TCRs 
enriched in C2TAkd animals compared to animals with MHC II deficient bone marrow, 
suggesting that while mTECs are capable of mediating clonal deletion, their relative 
contribution is minimal compared to bone marrow APCs (45). 
1.3.2 Medullary Thymic Epithelial Cells and Regulatory T cell Differentiation 
A study in which mTECs were shown to induce development of Tregs specific for 
an AIRE-dependent model antigen gave the first indication that AIRE-expressing mTECs 
may also impact tolerance through shaping the Treg repertoire (46). Indeed, it was 
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recently shown that organ-specific Tregs required AIRE-mediated expression of the self-
antigen (47, 48). Although polyclonal Treg numbers are not dramatically altered in the 
absence of AIRE, at least in adult mice (40, 49), AIRE may play a major role in directing 
specific T cell clones into the Treg lineage. Therefore, strategies to analyze the impact of 
AIRE and mTECs at the TCR-level have been employed. One approach took advantage 
of using a fixed TCR-β chain to enable analysis of TCR specificities via sequence 
analysis of the TCRα chain (45, 50, 51). Perry et al. performed high throughput analysis 
of the TCR Vα2 repertoire in animals lacking MHC II on bone marrow APCs or in 
C2TAkd animals. Like with clonal deletion, mTECs contributed less to Treg generation 
compared to bone marrow APCs. However, mTECs contributed substantially more to 
Treg induction than to clonal deletion at the repertoire level (45). Further TCR analysis in 
AIRE deficient mice revealed that AIRE plays a major role in selecting the thymic Treg 
TCR repertoire, particularly on lower frequency TCRs (45). 
Similarly, Malchow et al. performed deep sequencing of the complete TCRα 
repertoire in isolated peripheral Treg and conventional T cells in AIRE-sufficient or -
deficient animals. This study found a large number of underrepresented Treg TCRs in 
AIRE-deficient animals. Interestingly, in the absence of AIRE, these clones were 
identified in the conventional T cell repertoire. A major proportion of the clonotypes 
mediating autoimmune pathology in AIRE deficient animals are preferentially expressed 
by Tregs in AIRE-sufficient animals, suggesting that a major mechanism by which AIRE 
enforces central tolerance is directing autoreactive conventional TCR clones into the 
regulatory T cell lineage (51). 
Recent data also suggest that the AIRE-dependent Treg repertoire is distinct 
during different points in ontogeny and that these repertoires may be responsible for 
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protecting separate tissues. Despite similar fractions of MHC IIhi mTEC and AIRE 
expression in perinatal and adult mice, the differences mediating this age-dependent 
selection of the Treg repertoire seem to lie in distinct antigen processing and 
presentation machinery capabilities. Perinatal mTECs had a decreased DO to DM ratio 
compared to adult mTECs. DM aids in the removal of the invariant chain derivative, 
CLIP, and other peptides from MHC II, while DO is known to inhibit this action. 
Therefore, perinatal mTECs had a corresponding decrease in the amount of CLIP, 
suggesting that perinatal mTECs are more efficient at replacing CLIP with other peptides 
and that the peptide repertoire presented by MHC II may therefore be more broad in 
perinatal mTECs (49). These data support the notion that AIRE is essential to central 
tolerance during the neonatal period, but dispensable in adults (52).  
Although AIRE’s role in mediating Treg differentiation has been more thoroughly 
investigated, Fezf2 may also play an essential role in Treg lineage commitment. Fezf2 
deficient animals have decreased frequencies of thymic Tregs, indicating that Fezf2 may 
play an even more substantial role in mediating thymic Treg development (37). Further 
analysis comparing the TCR repertoires of Tregs and conventional T cells in Fezf2 
deficient animals will be necessary to determine if Fezf2 similarly directs TCRs from the 
conventional T cell pool into the Treg lineage. 
While the relative importance of the contribution of AIRE-dependent clonal 
deletion and Treg induction to tolerance in not known, the studies discussed above 
suggest that AIRE-mediated Treg induction may be the crucial mechanism by which 
AIRE enforces tolerance. Several studies have recently suggested that clonal deletion of 
T cells specific for self-antigens and TRAs is incomplete (42, 53–56). T cells specific to 
an epitope of the AIRE-dependent retina-specific protein interphotoreceptor retinoid 
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binding protein (IRBP) were incompletely deleted via an AIRE-dependent mechanism 
(55). Furthermore, through the use of a model utilizing Cre recombinase as a neo-self 
antigen, Legoux et al. were able to track Cre tetramer-specific CD4 T cells in various 
mouse strains where Cre expression was restricted to specific peripheral tissues. 
Although efficient deletional tolerance was found in animals which ubiquitously 
expressed Cre, when the epitope was restricted to peripheral tissues, Cre:I-Ab specific T 
cell numbers were not decreased in either the thymus or the periphery, suggesting a 
lack of deletional tolerance (54). Furthermore, tolerance to some tissue specific 
antigens, such as lung and intestine self-antigens, required antigen-specific Tregs (54). 
Another study that used a similar model to investigate antigen-specific tolerance to 
fluorescent proteins expressed by various tissue specific promoters came to similar 
conclusions. Malhotra et al. defined three clusters of self-specific cells. The first cluster is 
characterized by wild type numbers of cells with relatively few regulatory T cells, 
suggesting that these cells did not encounter their epitope. Thus, the mechanism 
mediating tolerance for cluster 1 was likely ignorance. The second cluster resembled 
that of the lung and intestine-specific cells reported by Legoux et al., in which there were 
relatively large numbers of Treg cells and few effector cells. Finally, the mechanism 
mediating tolerance to the third cluster was deletion, which also included T cells specific 
for ubiquitously expressed proteins (42). These data suggest that the mechanism of 
tolerance for a specific epitope may not be solely mediated by the APC type, but may 
also depend on its relative expression within the thymus. 
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Figure 1.1. Antigen presenting cells encountered in the thymus. 
  
The thymus plays an essential role in mediating self-tolerance by selecting a T cell receptor 
repertoire based on self-antigens presented by thymic antigen presenting cells (APCs). Thymic 
APCs include cortical and medullary thymic epithelial cells (cTEC and mTEC), thymic dendritic 
cells (DC), and B cells. Self-antigens are presented in the thymus via multiple mechanisms. cTEC 
present antigens specialized for positive selection through their use of the unique proteolytic 
subunit, β5t. The autoimmune regulator, AIRE, promotes presentation of tissue-restricted self-
antigens (TRA) on both mTECs and B cells. Additionally, thymic APCs rely on distinct 
chemotactic cues for localization within the thymus. These cues, at least in part, govern the 
unique self-peptides presented by distinct thymic APCs. cDC1 express XCR1, which allows them 
to localize next to mTEC and acquire mTEC-derived TRAs. cDC2 and plasmacytoid DC (pDC) 
can acquire antigen in the periphery and present that antigen in the thymus. The chemokine 
receptors expressed by cDC2 and pDC (CCR2 and CCR9 respectively) may determine the 
unique self-antigens presented by these two DC subsets. Although a mechanism is yet to be 
defined, current data suggest that specific medullary APCs favor distinct methods of T cell 
tolerance– clonal deletion vs. regulatory T cell differentiation. 
 
1.4 Thymic Dendritic Cells 
Three universally defined dendritic cell (DC) subsets have been described within 
the thymus (57). These subsets include plasmacytoid DC (pDC) and two conventional 
DC (cDC) populations, which are delineated based on their expression of lineage-
defining cell surface markers and transcription factors (57, 58) (Figure 1.1). cDC1 are 
  14 
defined based on their expression of the chemokine receptor, XCR1 (XC-chemokine 
receptor 1), and require the transcription factor IRF8. Alternatively, cDC2 express SIRPα 
(signal regulatory protein alpha, CD172a) and require the transcription factor IRF4 (58). 
These DC subsets are uniquely primed to process and present distinct antigens based 
on their functional specialization and their ability to respond to different migratory cues. 
cDC1 are specialized to cross-present mTEC-derived self-antigens and 
accumulate in the medulla in an XCR1-dependent manner. XCL1 (XC-chemokine ligand 
1 or lymphotactin), the ligand for XCR1, is produced by mTEChi cells in an AIRE-
dependent manner, indicating that XCR1 expression facilitates the transfer of mTEC 
derived TRAs for cross-presentation (59–61). Recent evidence suggests that these 
cDC1 undergo constant homeostatic maturation within the thymus; mature cDC1 
express CCR7 and upregulate MHC II, CD40, CD83, and CD86. In contrast to immature 
(CCR7 negative) cDC1, only mature cDC1 are able to cross-present mTEC-derived 
antigens (62). Therefore, this maturation process is likely essential for efficient self-
antigen presentation in the thymus; immature cDC1 may not contribute to or may play a 
distinct role in driving central tolerance compared to their mature counterparts. The 
factors that control thymic DC maturation have not yet been defined. 
In contrast to cDC1, cDC2 originate in the periphery and are capable of acquiring 
serum-antigens and/or transporting self-antigens into the thymus (57, 63, 64). C-C 
chemokine receptor 2 (CCR2) dictates cDC2 migration into the thymus (64). Although 
both cDC1 and cDC2 localize within the medulla, cDC2 may also accumulate within the 
perivascular region of the cortex (27, 64). However, the specific site in which this subset 
accumulates within the thymus remains controversial and the specific chemotactic 
signals that are required for localization are unknown (1, 64). pDCs also migrate to the 
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thymus from peripheral sites, however the thymic homing of this subset is CCR9-
dependent (65, 66). Like cDC2, pDC are capable of acquiring self-antigens in the 
periphery and homing to the thymus to present antigens to developing thymocytes (66). 
The distinct chemotactic requirements and antigen presenting capabilities of the 
DC subsets suggests that they may play unique functional roles in facilitating selection of 
the T cell repertoire.  
1.4.1 Thymic Dendritic Cells and Clonal Deletion 
Although the relative contribution of bone marrow APCs and mTECs to clonal 
deletion is unknown, recent studies examining negative selection at the individual TCR 
level suggest that bone marrow-derived APCs contribute more to clonal deletion than 
mTECs (45, 67). This makes sense, given that the majority of clonal deletion occurs in 
the cortex compared to the medulla and that migratory cDC2 can localize in the cortex 
(64, 67–70). 
Recently, a MacNabb et al. investigated the role of cDC1 in shaping the CD8+ 
thymocyte TCR repertoire (71). Through analysis of deep TCR sequencing, this group 
reported that cDC1 did not impact the CD8+ T cell repertoire. Because cDC1 cross-
present TRA acquired from mTEC, this may suggest functional redundancy between 
cDC1 and mTEC in mediating selection of the CD8+ T cell repertoire. However, using a 
similar approach, another group demonstrated a BATF3-dependent role for clonal 
deletion of both conventional CD4+ T cells and Treg (61). 
Because cDC2 are capable of acquiring self-antigens in the periphery and 
transporting them to the thymus, it has been suggested that they mediate tolerance to 
extrathymic antigens (57, 63, 64). Indeed, OVA-specific thymocytes underwent clonal 
deletion mediated by circulating DCs in a model in which OVA was expressed 
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exclusively by cardiomyocytes (63). Interestingly, cDC2 express the highest levels of the 
CCR4 ligands, CCL17 and CCL22 (72). CCR4 is required for thymocyte migration from 
the cortex to the medulla (26). Although thymic cellularity in CCR4 deficient animals is 
mostly unaffected compared to wild type animals, mixed CCR4 deficient and wild type 
bone marrow chimeras revealed a relative increase in CCR4 deficient CD69+ thymocyte 
populations compared to wild type thymocytes, implying that CCR4-mediated 
thymocyte–cDC2 interactions are required for efficient clonal deletion (27).  
Recent evidence also suggests that there may be variability in the relative 
contribution of these dendritic cell subsets to clonal deletion over time. The frequency of 
both cDC2 and pDC populations was increased in 4-week-old non-obese diabetic (NOD) 
mice compared to their newborn counterparts (73). Additionally, antigen processing and 
presentation was enhanced in cDC2 from four-week-old mice compared to cDC2 from 
newborns (73). The frequency of cDC1 in the thymus may also be age-dependent. 
Perinatal NOD mice had nearly 1/3rd of the frequency of cDC1 compared to adults (49). 
This is in direct contrast to findings reported by Kroger et al., who suggest that newborn 
NOD mice have a larger proportion of cDC1 compared to 4 week old NOD mice (73). 
Although the explanation for this discrepancy is unclear, these contradictory findings 
might be justified by differences in gating strategies, housing conditions, or NOD strains. 
Additionally, neither group reported cDC1 cell numbers when comparing perinatal to 
adult mice, which may be more indicative of the temporal changes in this cell population. 
Overall, the idea of age dependent differences in DC composition is interesting and may 
consequently result in changes in clonal deletion and Treg cell development, however 
further studies are needed to more directly define these changes. 
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As mentioned above, thymic dendritic cells seem to contribute to a large 
proportion of the deletional tolerance to AIRE-dependent TRAs (42, 55). Thymic DCs 
mediate AIRE-dependent deletion of T cells specific for IRBP epitope (55). Additionally, 
in the cluster system described by Malhotra et al. (see Section 1.3.2), a major proportion 
of DCs expressed cluster 3 antigens, in which deletion was the major tolerance 
mechanism, compared to clusters 1 and 2, in which ignorance or Treg induction were 
the major mechanisms of tolerance (42).  
Because of their capability to produce type I interferons during viral infections 
(74) and their poor antigen presenting capacity compared to cDC, it was largely believed 
that pDC assumed an immunomodulatory function within the thymus (75, 76). However, 
evidence now suggests that pDC may play a role in mediating central tolerance as well. 
Wild type pDC loaded with OVA peptide and adoptively transferred, migrated to the 
thymus and promoted deletion of OVA-specific OT-II thymocytes, whereas CCR9-
deficient pDC did not (66). Furthermore, because CCR9 is also essential for pDC 
homing to the small intestine during both homeostatic and inflammatory conditions (77), 
pDC may mediate tolerance to commensal or food antigens within the thymus, however 
this hypothesis has not been tested to date. 
1.4.2 Thymic Dendritic Cells and Regulatory T Cell Differentiation 
Both cDC1 and cDC2 are capable of promoting Treg induction in vivo (76, 78, 
79), and it has been suggested that cDC2 are more efficient at driving Treg 
differentiation in vitro (79). Interestingly, several recent studies suggest that bone 
marrow APC play a critical role in promoting selection of AIRE-dependent Treg clones 
(45, 48, 61, 80). However, there are conflicting reports about whether cDC1 and cDC2 
are redundant in their roles for AIRE-dependent Treg selection. Perry et al. 
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demonstrated a non-redundant role with data showing that cDC1 were required for the 
selection of four AIRE-dependent Treg clones. However, utilizing high throughput TCR 
analysis comparing cDC1-sufficient and -deficient animals, Leventhal et al. concluded 
that cDC1 did not have an impact on the Treg TCR repertoire. One explanation may be 
related to the analysis method. Perry et al. showed that removal of the three most 
frequent TCR specificities from analysis was required to determine a difference in Treg 
TCR repertoires in C2TAkd and WT animals (45). However, Leventhal et al. did not 
utilize this strategy to assess similarity between cDC1-dependent Treg TCRs. 
pDC can also promote the development of Treg in vitro (81), however their role in 
mediating Treg differentiation in vivo is unclear. pDC did not have an effect on Treg 
selection of four bone marrow APC-dependent TCRs (45), however the precise role of 
pDC in mediating Treg selection of the polyclonal repertoire is unknown. 
In addition to their role in mediating the TCR-dependent first step of Treg 
differentiation, DCs may also instruct the second step of Treg development, which 
requires interleukin (IL)-2 and IL-15 cytokine signals (82). It was previously believed that 
thymocytes were the major producers of IL-2 in the thymus, however a recent study 
using thymic tissue slices found that thymic DCs provide a local source of IL-2 to 
developing Tregs (83). Therefore, distinct APC subsets within the thymus may cooperate 
to drive thymic Treg differentiation. 
The distinct contributions of cDC1 and cDC2 to central tolerance remain to be 
tested. Unfortunately, no current method exists to specifically deplete cDC2 (84). 
Therefore, new tools are needed to assess the relative contribution of cDC1 and cDC2 
to both clonal deletion and Treg differentiation. Additionally, the relative importance of 
antigens acquired in the periphery compared to those acquired in the thymus is 
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unknown. Does the functional specialization of cDC2 change depending on the location 
of where antigen is acquired? Do intrathymic and extrathymic self-antigens favor 
different tolerance mechanisms? Is tolerance to commensal and food antigens mediated 
in the thymus as well as in the periphery? 
 
1.5 Thymic B Cells 
Although thymic B cells comprise a similar proportion of total thymic cells 
compared to DCs and mTECs, relatively little is known about their function in the thymus 
(85). However, their localization in the medulla and cortico-medullary junction suggests 
that thymic B cells may play an integral role in mediating Treg development and deletion 
of autoreactive T cell clones (Figure 1.1) (86, 87). In support of this notion, thymic B cells 
seem exceptionally primed to present antigens; compared to splenic B cells, thymic B 
cells have markedly increased expression of MHC II and co-stimulatory molecules, 
including CD80 and CD86 (85–87). 
Whether thymic B cells arise and develop in the thymus or circulate from the 
periphery and adopt a new phenotype remains unclear, however it is likely that both 
occur (85, 87, 88). It is evident that the thymic microenvironment is important for driving 
B cell functions that are distinct from those of the periphery. Notably, licensed thymic B 
cells express AIRE, whereas peripheral B cells do not (85). Thymocyte interactions with 
B cells promote B cell licensing much in the way that they orchestrate mTEC maturation, 
in that in both cases, thymocytes provide TNFRSF stimulation to induce AIRE 
upregulation. CD40 is critical for the maintenance of thymic B cells and MHC II-restricted 
cognate interactions drive thymic B cell class switching and AIRE expression, indicating 
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that cognate interactions between B cells and T cells may be essential for driving central 
tolerance (85, 89). 
Recently, Nuñez et al. demonstrated that memory B cells accumulate within the 
perivascular space of the human thymus in an age-dependent manner (90). However, 
the expression of molecules associated with antigen presentation decreased in B cells 
from older thymi, suggesting that B cells may become less integral to T cell selection 
over time, at least in humans (90). Whether this represents a distinct niche from other 
thymic B cells is not clear, since a similar phenomenon is not seen in mice (89).  
1.5.1 Thymic B Cells and Clonal Deletion 
It is evident that thymic B cells can mediate clonal deletion, as B cells have been 
shown to delete T cells in the context of superantigen and in systems with model 
antigens (89, 91, 92). More recently, it has been suggested that self-specific B cells 
present cognate antigen to autoreactive T cells (87). KRN T cells, specific for a peptide 
from the self-protein glucose-6-phosphate isomerase (GPI), were deleted by B cells with 
a transgenic B cell receptor (BCR) specific for GPI and by wild-type I-Ag7 thymic B cells 
(87). This would suggest that autoreactive B cells within the thymus acquire self-antigen 
via BCR-mediated endocytosis and mediate tolerance through cognate interactions (87). 
However, BCR-independent presentation of endogenous self-antigens may also be an 
important mechanism by which B cells mediate central tolerance. Licensed B cells 
directly presented an endogenously expressed antigen and mediated clonal deletion of T 
cells specific for that antigen (85). Interestingly, BCR cross-linking in the presence of 
CD40 signaling suppressed AIRE induction in thymic B cells, but not MHC II 
upregulation (85). These findings suggest that both AIRE-expressing and non-
expressing B cells in the thymus are capable of mediating clonal deletion. Although more 
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studies are required to delineate a specific mechanism, this evidence indicates that 
AIRE-expressing B cells may drive tolerance to endogenous antigens, whereas B cells 
that do not express AIRE may direct tolerance to BCR-acquired antigens.  
B cells may also play a critical role in driving tolerance to B cell-specific antigens; 
B cells present B cell-specific peptides on MHC II, including variable region peptides (93, 
94). Interestingly, recent evidence suggests that thymic B cells undergo class switching, 
but not somatic hypermutation within the thymus. Class switching is dependent on 
cognate interactions between B and T cells in the thymus. In the absence of activation 
induced cytidine deaminase (AID), which is required for class switching, the T cell 
repertoire is more autoreactive (88). This implies that class switched B cells assist in 
mediating tolerance of the T cell repertoire. Although the mechanism by which class 
switching promotes deletion of autoreactive T cells is unclear, class switching may be 
important for B cells to function as antigen presenting cells, and the class switched B cell 
may display a distinct MHC II-bound self-peptidome that necessitates T cell tolerance. 
There is much to be learned in the future about how B cells shape the polyclonal T cell 
repertoire. 
1.5.2 Thymic B Cells and Regulatory T Cell Differentiation 
B cells also play a striking role in the development of thymic Tregs. The number 
and frequency of thymic Tregs is decreased by approximately one third in the absence 
of B cells (86, 95). Additionally, in BAFF transgenic mice, which have an expansion of 
extrasplenic B cells, the number and frequency of thymic Treg is increased nearly two-
fold (95). This B cell-mediated induction of thymic Tregs is dependent on direct 
interactions with MHC II and co-stimulatory molecules (86, 95). Additionally, in vitro 
experiments suggest that thymic B cells are capable of directing development of 
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CD4+CD25+ Treg precursors, but are not required for the second stage of development 
into mature Tregs, which requires the cytokines IL-2 or IL-15 (86, 96). Whether AIRE-
dependent Tregs arise out of cognate interactions with B cells is unclear (80). However, 
given the strong expression of TRA transcripts by AIRE-expressing thymic B cells, it will 
be interesting to see if AIRE expression in B cells contributes distinctly to the Treg TCR 
repertoire compared to mTECs (45, 85). 
 
1.7 Conclusions and Future Directions 
Recent studies evaluating the non-redundant roles by which distinct APC subsets 
mediate thymocyte selection are providing new insights into how the TCR repertoire is 
shaped. Although the affinity between TCR and self-peptide–MHC may remain the 
driving factor in thymocyte selection, the context in which self-peptide is presented is 
becoming an increasingly important factor in determining thymocyte fate. APC subsets 
within the thymus are localized based on discrete stromal cues and shape the 
architecture in which thymocytes are selected. Furthermore, each subset provides a 
distinct framework in which thymocytes are selected, including chemokines, cytokines, 
and unique self-peptides (Figure 1.1). 
Defining the non-redundant functional capabilities of distinct APC subsets remain 
major ambitions of future investigations. Until we have a more complete understanding 
of the various roles of thymic APCs, we will not fully understand if and how the 
breakdown of central tolerance contributes to human autoimmune diseases. A 
comprehensive understanding of the thymic APCs required for appropriate selection of 
the T cell repertoire is also needed as the field seeks to develop methods of stem cell-
based T cell production for purposes of therapeutic T cell reconstitution. 
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Chapter 2 
 
 Measuring thymic clonal deletion at the population level 
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2.1 Introduction 
Clonal deletion in the thymus eliminates self-reactive T cells, resulting in a T cell 
repertoire that is tolerant to self-peptides, but is well equipped to respond to foreign 
pathogens. The strength of the interaction between the T cell receptor (TCR) and self-
peptide–MHC complexes is critical to this process, where strong interactions induce 
death by apoptosis and weak interactions promote survival and maturation. Importantly, 
clonal deletion occurs within discrete microenvironments within the thymus: the cortex 
and the medulla. The medulla is considered a specialized site for negative selection 
because of AIRE (autoimmune regulator)-mediated expression of tissue-specific 
antigens and the high concentration of dendritic cells relative to the cortex (1). However, 
recent studies challenged this conception, suggesting that the majority of clonal deletion 
occurs at the double positive (DP) stage in the thymus cortex in a process independent 
of the medulla (67, 68, 70). Nevertheless, the developmental stages at which 
thymocytes undergo clonal deletion, their corresponding anatomic locations, and the 
relative proportions at which they undergo clonal deletion at these developmental stages 
remains controversial.  
The reason for this controversy lies primarily in the use of different model 
systems that have confounded our understanding of clonal deletion in the polyclonal 
repertoire. Models including the use of endogenous superantigens fail to emulate 
antigen-specific clonal deletion. TCR transgenics have been used extensively to study 
clonal deletion and more appropriately model an antigen-specific response to either 
exogenous peptide injection or endogenous self-peptide. However, the high frequency of 
a single specificity of antigen-specific T cells results in a number of nonphysiologic 
effects (97–99). Additionally, TCR transgenics express their TCR early during 
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development at the double-negative (DN) stage, whereas wild-type (WT) thymocytes do 
not express surface TCR until the DP stage of development. This results in premature 
clonal deletion at anatomic locations that are not representative of the polyclonal 
repertoire (100–102).  
More recent studies have attempted to study clonal deletion in settings more 
representative of the polyclonal environment. BIM deficient mice have an accumulation 
of self-reactive thymocytes and can therefore be utilized to enumerate T cells that were 
rescued from clonal deletion (68). This study demonstrated that approximately 75% of 
thymocytes undergo clonal deletion within the thymus cortex. However, the marked 
accumulation of thymocytes is not representative of the physiologic conditions in WT 
mice. A conditional retroviral TCR expression system (retrogenic mice), reported similar 
conclusions to the BIM knockout studies that approximately 85% of thymocytes undergo 
clonal deletion in cortex, however only 12 distinct TCRs that were negatively selected 
were analyzed (67). Finally, peptide–MHC class II tetramers provide a remarkable tool to 
study tolerance in specific clones within the polyclonal CD4+ T cell repertoire (42, 103), 
but because of their very small numbers, the anatomic locations at which these clones 
are deleted are difficult to assess and do not provide a picture at the population level.  
Given this, we sought to develop a tool to evaluate clonal deletion in the 
polyclonal repertoire of WT mice. We designed a cleaved caspase 3-based assay and 
validated it by a number of different approaches. Using CCR7 to approximate anatomic 
location in the thymus, we delineate the fraction of thymocytes undergoing clonal 
deletion in the thymus cortex compared to the medulla. Surprisingly, thymocytes 
continue to undergo clonal deletion at the most mature stages of development in the 
thymus medulla. We also report a critical role for CD28-mediated co-stimulation for 
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clonal deletion both within the thymus cortex and medulla. These findings provide a 
valuable strategy for studying clonal deletion under normal physiologic and pathologic 
conditions.
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2.2 Results 
2.2.1 Identifying clonal deletion in the polyclonal repertoire 
We sought to develop a flow cytometry-based assay to identify thymocytes 
undergoing apoptosis by clonal deletion. Cells activate a cascade of death inducers 
when undergoing apoptosis, including cleaved caspase 3, which can be detected by 
intracellular staining. However, in the thymus, caspase 3 is cleaved in cells undergoing 
apoptosis due either to death by neglect or clonal deletion. To differentiate between 
these two fates, we used CD5 and T cell receptor (TCR) b, which are upregulated upon 
T cell receptor signaling (104). Cleaved caspase 3+ CD5+ TCRb+ cells (red gate, Figure 
2.1A) potentially represent cells undergoing clonal deletion. To verify this possibility, we 
utilized Nur77GFP reporter mice, in which GFP expression approximates TCR signal 
strength (105, 106). GFP expression was high in cells presumed to be undergoing clonal 
deletion (CD5+TCRb+cleaved caspase 3+), whereas cells undergoing death by neglect 
(CD5-TCRb-cleaved caspase 3+) did not express GFP (Figure 2.1B). Additionally, GFP 
expression was higher in cells undergoing clonal deletion compared to the total 
population of signaled cells “auditioning for selection,” consistent with the affinity model 
for selection that proposes that strong TCR–self-peptide–MHC interactions are required 
to induce clonal deletion (1). In line with this, the frequency of cells undergoing clonal 
deletion was highest in signaled thymocytes that expressed the most GFP and 
decreased as GFP expression decreased (Figure 2.1C). We also evaluated mice lacking 
Bim (BIM KO), which is a proapoptotic molecule required for clonal deletion (68). The 
frequency of CD5+TCRb+cleaved caspase 3+ cells was profoundly decreased in Bim KO 
mice (Figure 2.1E).  
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To further verify this assay, we examined TCR transgenic thymocytes 
undergoing either positive or negative selection. We reasoned that T cells with TCRs 
that do not have an epitope expressed in the thymus would not undergo clonal deletion, 
whereas TCRs that have an epitope that is over-expressed in the thymus would have an 
increased proportion of thymocytes that undergo clonal deletion. To do this, we 
generated 3-way mixed bone marrow chimeras that were 45% SMARTA (CD4+ TCR 
specific for LCMV GP61-80), 45% OT-II (CD4+ TCR specific for OVA323-339), and 10% WT 
bone marrow (Figure 1F and G). Congenic recipient mice were either WT or RIP-mOVA, 
which ectopically express OVA peptide under the control of the rat insulin promoter in 
the thymus. OT-II thymocytes had a high frequency of CD5+TCRb+cleaved caspase 3+ 
cells in RIP-mOVA recipients, but not in WT recipients (Figure 2.1G). Likewise, the 
frequency of such cells amongst SMARTA thymocytes was quite low in either recipient 
(Figure 2.1G). Altogether, these data support the validity of this approach for identifying 
thymocytes undergoing clonal deletion within the polyclonal repertoire. 
To determine the localization of thymocytes undergoing clonal deletion, we 
stained for the C-C chemokine receptor CCR7, which is required for migration to the 
thymus medulla (26–31) (Figure 2.1A). Approximately 22% of the thymocytes 
undergoing clonal deletion were CCR7+ (Figure 2.1D), which is consistent with previous 
reports that the majority of clonal deletion occurs in the thymus cortex (67, 68). 
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Figure 2.1. Cleaved caspase 3 distinguishes thymocytes undergoing clonal 
deletion.  
 
(A) Flow cytometry gating strategy for the identification of cells undergoing clonal 
deletion or death by neglect in the thymus. Signaled and non-signaled thymocytes 
identified by the expression of CD5 and TCRb, excluding CD25+, NK1.1+, CD19+, and 
TCRgd+ (Dump) cells (top). Clonal deletion and death by neglect identified by the 
expression of cleaved caspase 3 (middle) and approximate anatomic location identified 
by CCR7 (bottom). Numbers adjacent to outlined areas indicate percent cells in each. 
(B) Flow cytometry from Nur77GFP mice showing GFP expression by CD5-TCRb-cleaved 
caspase 3+ (neglect) CD5-TCRb- (non-signaled), CD5+TCRb+ (signaled), and 
CD5+TCRb+cleaved caspase 3+ (deletion) (as demonstrated in A). (C) Flow cytometry 
from Nur77GFP mice showing gating based on GFP expression (approximately 15% of 
total CD5+TCRb+ cells per gate) (left) and frequency of cleaved caspase 3 expression 
among CD5+TCRb+ (signaled) thymocytes in each gate (right). (D) Frequency of CCR7- 
or CCR7+ among clonally deleted cells (as shown in A). (E) Frequency of cleaved 
caspase 3+ cells among CD5+TCRb+ thymocytes (as gated in A) from BIM WT or BIM 
KO littermates. (F) Experimental design used to generate bone marrow chimeric mice. 
(G) Frequency of cleaved caspase 3+ cells among CD5+TCRb+ (signaled) thymocytes 
(as gated in A) from bone marrow chimeric mice (as in F). Each symbol (C, D, E) 
represents an individual mouse. Six- to twelve-week-old male and female mice were 
used. Small horizontal lines indicate the mean and error bars represent SEM. *P< 0.05, 
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**P< 0.01, ***P< 0.001, ****P< 0.0001. Statistical significance was determined by Mann-
Whitney test (E) or 2way Anova with Dunnett’s and Sidak’s multiple comparisons tests 
(G). Data are representative of more than ten experiments (A, B, C, D) or are pooled 
from two (E, G) independent experiments with at least three mice per group. 
 
2.2.2 Mature thymocytes undergo clonal deletion 
Thymocytes in the medulla undergo distinct stages of maturation, during which 
they become competent to produce cytokines, proliferate, and emigrate (107). A seminal 
study by Kishimoto and Sprent (108), showed that semi-mature SP thymocytes undergo 
apoptosis when stimulated with anti-CD3, whereas the most mature SP thymocytes tend 
to proliferate (108, 109). Thus, we expected most CCR7+CD5+TCRb+cleaved caspase 3+ 
cells would be of the “semi-mature” phenotype. CD69 and MHCI staining was used to 
define three distinct stages of SP maturation: CD69+MHCI- semi-mature (SM), 
CD69+MHCI+ mature 1 (M1) and CD69-MHCI+ mature 2 (M2) (109). To our surprise, all 3 
stages were present amongst CCR7+ CD5+TCRb+cleaved caspase 3+ cells—those 
undergoing deletion in the medulla (Figure 2.2A, top), which suggests that even mature 
thymocytes can undergo deletion. When examining the frequency of clonal deletion 
events at each stage, we observed only a modest reduction from the SM to M1 to M2 
stages (Figure 2.2B and C). To confirm that the mature phenotype deleted cells truly 
were later in differentiation, we performed this assay using RAG2GFP mice (where GFP 
decay acts as a ‘molecular timer’ from positive selection) (110). GFP decay was 
equivalent in clonally deleted and non-deleted thymocytes at more mature stages 
(Figure 2.2A, bottom) confirming that deletion can occur far after positive selection. To 
verify that these late stage clonal deletion events were due to strong TCR signals (as 
opposed to failed positive selection), we utilized Nur77GFP reporter mice. GFP expression 
was higher in thymocytes undergoing clonal deletion in all three stages of maturation 
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(Figure 2.2D). These data indicate that even the most mature thymocytes can undergo 
TCR triggered apoptosis. 
It was previously established that thymocytes are more susceptible to Treg 
induction as they mature (81).  Given that Treg induction can lead to apoptosis if it falters 
(111), we considered the possibility that many of the late stage deletion events might be 
due to failed Treg induction. Consistent with this idea, we observed that the percentage 
of FOXP3+/CD25+ cells amongst deleted thymocytes was increased with maturation 
(Figure 2.2E). 
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Figure 2.2. Mature thymocytes are susceptible to clonal deletion. 
 
(A) Flow cytometry of total or deleted CD5+TCRb+ medullary (CCR7+) CD4+ thymocytes 
from Rag2GFP mice (gated as in Figure 2.1A). Gates of three subsets of medullary 
thymocytes based on expression of CD69 and MHC I (top), and GFP expression by 
CD69+MHC I- (SM), CD69+MHC I+ (M1), and CD69-MHC I+ (M2) cells (bottom). Numbers 
adjacent to outlined areas indicate percent cells in each. (B) Flow cytometry of deleted 
thymocytes (as gated in Figure 2.1A) of cortical (CCR7-) DP or medullary (CCR7+) CD4+ 
subsets. Numbers adjacent to outlined areas indicate percent cleaved caspase 3+ cells 
in each. (C) Frequency (left) and numbers (right) of cleaved caspase 3+ thymocytes 
among CD5+TCRb+ thymocyte subsets or CD4+ splenocytes from Rag2GFP mice (gated 
as in Figure 2.1A). (D) Flow cytometry of deleted or non-deleted thymocytes (as gated in 
Figure 2.1A) from Nur77GFP mice (left) and geometric mean fluorescence intensity (gMFI) 
normalized to controls (right). (E) Frequency of CD25+ or FOXP3+ among 
CD5+TCRb+CD4+cleaved caspase 3+ thymocytes negatively enriched for CD4 using 
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MACS purification from bone marrow chimeric mice that received FOXP3GFP bone 
marrow. Data are representative of more than 5 independent experiments (A, B, C, D) or 
2 independent experiments (E). Each symbol (C, D) represents an individual mouse. 
Six- to twelve-week-old male and female mice were used. Small horizontal lines indicate 
the mean and error bars represent SEM. *P< 0.05, **P< 0.01, ***P< 0.001. Statistical 
significance was determined by one-tailed Mann-Whitney test (D) or ordinary one-way 
ANOVA with Tukey multiple comparisons test (E). 
 
 
2.2.3 Contribution of bone marrow APC to clonal deletion in the polyclonal 
repertoire 
Both bone marrow-derived APCs and medullary thymic epithelial cells (mTEC) 
have been shown to mediate clonal deletion (112). We reasoned that this assay could 
be used to assess the relative contribution of bone marrow APCs to deletion in the 
polyclonal repertoire. For this, WT or MHC II-deficient mice (MHC II KO) were used as 
bone marrow donors into irradiated WT recipient mice (Figure 2.3A, Figure 2.4). We did 
not assess MHC II-deficient recipients, because lack of MHC II on cortical thymic 
epithelial cells prevents positive selection of CD4+ T cells. Bone marrow APCs 
contributed to approximately 43% of clonal deletion events in the thymus cortex (Figure 
2.3B) and 41% of clonal deletion events in the thymus medulla (Figure 2.3C). These 
data show that bone marrow APCs contribute to a substantial proportion of non-
redundant clonal deletion events in the polyclonal repertoire. 
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Figure 2.3. Bone marrow derived APC contribute to approximately half of clonal 
deletion events.  
 
(A) Experimental strategy for generating bone marrow chimeric mice. (B) Frequency of 
cleaved caspase 3+ thymocytes among CD5+TCRb+ cortical (CCR7-) thymocytes (as 
gated in Figure 2.1A). (C) Frequency of cleaved caspase 3+ thymocytes among 
CD5+TCRb+ medullary (CCR7+) CD4+ thymocytes (as gated in Figure 2.1A). Each 
symbol (B, C) represents an individual mouse. Six- to twelve-week-old female mice were 
used. Small horizontal lines indicate the mean and error bars represent SEM. *P< 0.05, 
**P< 0.01. Statistical significance was determined by Mann-Whitney test (B, C). Data are 
pooled from two independent experiments. 
 
 
 
Figure 2.4. MHC II KO bone marrow chimera efficiency.  
 
(A) Flow cytometry of total thymocytes from bone marrow chimeric mice from either WT 
donor (left) or MHC II KO donor (right) mice (as shown in Figure 2.3A). Numbers 
adjacent to outlined areas indicate percent CD45.1+ (recipient) cells in each. (B) 
Frequency CD45.2+ (donor cells) of total thymocytes for each bone marrow chimeric 
donor. Each symbol represents an individual mouse (B). Six- to twelve-week-old female 
mice were used. Data are representative of two independent experiments (A) and 
pooled from two independent experiments (B).  
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2.2.4 Clonal deletion is dependent on co-stimulatory molecules in both the 
cortex and medulla 
Treg and iNKT cell development and survival in the thymus require CD80 and 
CD86 co-stimulation via the CD28 receptor (113–117). In contrast, other agonist 
selected cells– CD8aa intraepithelial lymphocyte precursors (IELp)– need to avoid 
CD28 co-stimulation for development (118, 119). However, the role of CD28-mediated 
co-stimulation in clonal deletion has been controversial, primarily because TCR 
transgenic and superantigen systems were utilized to assess negative selection (120). 
To address this, we evaluated clonal deletion in CD86 KO, CD80/CD86 KO, and CD28 
KO animals (Figure 2.5A). Consistent with previous reports, the frequency of CD4+ and 
CD8+ thymocytes was increased in CD80/86 KO animals (114, 121) (Figure 2.5B). CD28 
co-stimulation contributed to approximately half (56%) of clonal deletion events in the 
cortex and a third (36%) of clonal deletion events in the medulla (Figure 2.6A and B), 
indicating that CD28-mediated co-stimulation is required for clonal deletion. Surprisingly, 
CD86 alone contributed to clonal deletion in the cortex, but not the medulla (Figure 2.6A 
and B), raising the possibility of a non-redundant role for CD80 and CD86 in mediating 
clonal deletion. 
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Figure 2.5. Tolerance induction by CD80/CD86.  
 
(A) Flow cytometry of CD11c+ MHC II+ thymic dendritic cells from WT, CD86 KO, or CD80/86 KO 
mice (key) stained for CD80 (left) and CD86 (right). (B) Frequency of CD4+, CD8+, DP, and DN 
among total thymocytes from WT, CD86 KO, CD80/86 KO, and CD28 KO mice. (C) Flow 
cytometry of CD11c+ MHC II+ dendritic cells from WT mice stained for CD80 and CD86 (left) and 
quantification (right). Numbers indicate percent cells in each quadrant. (D) Flow cytometry of 
FcγR1+ MNPs from WT mice stained for CD80 and CD86 (left) and quantification (right). (E) Flow 
cytometric gating strategy for identifying CD25+ Treg progenitors, FOXP3+ Treg progenitors, and 
mature Treg (left). Frequency of CD25+ (middle, left), FOXP3+ (middle, right), or CD25+FOXP3+ 
(right) among CD4+ thymocytes from WT, CD86 KO, CD80/CD86 KO, and CD28 KO mice. Each 
symbol (B, E) represents an individual mouse. Six- to twelve-week-old male and female mice 
were used. Small horizontal lines indicate the mean and error bars represent SEM. **P< 0.01, 
***P< 0.001, ****P< 0.0001. Statistical significance was determined by ordinary one-way ANOVA 
with Holm-Sidak’s multiple comparisons test (B, E). Data are representative of at least three 
independent experiments (A) or are pooled from at least three independent experiments (B, C, D, 
E). 
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Figure 2.6. Co-stimulatory molecules CD80 and CD86 are required for both cortical 
and medullary clonal deletion.  
 
(A) Frequency of cleaved caspase 3+ cells among CD5+TCRb+ cortical (CCR7-) 
thymocytes (as gated in Figure 2.1A) in WT, CD86 KO, CD80/86 KO, and CD28 KO 
mice. (B) Frequency of cleaved caspase 3+ cells among CD5+TCRb+ medullary (CCR7+) 
CD4+ thymocytes (as gated in Figure 2.1A). (C) CD5 gMFI of cortical deleted thymocytes 
(normalized to mean of WT CD5 gMFI) (from A). (D) CD5 gMFI of medullary deleted 
CD4+ thymocytes (normalized to mean of WT CD5 gMFI) (from B). Each symbol (A, B, 
C, D) represents an individual mouse. Six- to twelve-week-old male and female mice 
were used. Small horizontal lines indicate the mean and error bars represent SEM. *P< 
0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001. Statistical significance was determined by 
ordinary one-way ANOVA with Holm-Sidak’s multiple comparisons test (A, B, C, D). 
Data are pooled from at least three independent experiments (A, B, C, D). 
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Given this, we sought to determine if CD86 was expressed in the absence of 
CD80 by any APC type in the thymus. Using flow cytometry of APC recovered from the 
thymus after collagenase digestion, we observed a substantial proportion of 
conventional dendritic cells (cDC) that expressed CD80 alone. However, no cDC 
expressed only CD86 (Figure 2.5C). Furthermore, no mononuclear phagocytes (MNPs) 
expressed CD86 alone (Figure 2.5D). To investigate the localization of CD80 and CD86, 
we utilized immunofluorescence staining and quantitative histo-cytometry to determine 
which APC subset could be mediating CD86-dependent clonal deletion events in the 
thymus cortex. In agreement with our findings by flow cytometry, very few cells localized 
within the thymus cortex or medulla expressed CD86 alone (Figure 2.7A, Figure 2.8A).  
Within the cortex, CD86 expression was observed on approximately 50% of CD11c-
expressing cells and on 70% of F4/80-expressing cells (Figure 2.7B and C, Figure 2.8B 
and C). Therefore, CD86-mediated clonal deletion in the cortex is likely mediated by 
both CD11c+ and F4/80+ APC. 
Because we could not explain the selective requirement for CD86 in cortical 
deletion by identifying a cortical APC that only expressed CD86, we reasoned that 
cortical thymocytes may be more sensitive to and dependent on interactions with 
CD80/CD86+ APC for clonal deletion. Indeed, in the absence of co-stimulation, the CD5 
gMFI was increased on clonally deleted thymocytes in the cortex (Figure 2.6C), 
indicating that only the most strongly signaled cells could be deleted without co-
stimulation. This was not the case of medullary thymocytes (Figure 2.6D). Consistent 
with this, CD86 alone was not required for Treg development, a process that also occurs 
in the thymus medulla (Figure 2.5E). Together, these data suggest that cortical 
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thymocytes have a lower threshold for co-stimulation-dependent negative selection 
compared to medullary thymocytes. 
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Figure 2.7 CD80 and CD86 are localized in both the thymus cortex and medulla.  
 
(A) Immunofluorescence microscopy (top) of thymic sections from C57BL/6 mice stained 
for CD80 (green), and CD86 (red). White dashed lines indicate cortical-medullary border 
based on UEA I staining (not shown). C, cortex; M, medulla. Scale bars 100µm. Analysis 
of images by histo-cytometry (bottom, left). Dots represent localization of each stain as 
determined by histo-cytometry. Frequencies of CD80+ and CD86+ cells identified as 
localized in the cortex by histo-cytometry (bottom, right). Numbers indicate percent cells 
in each outlined area. (B) Immunofluorescence microscopy (top) of thymic sections from 
C57BL/6 mice stained for CD11c (green), and CD86 (red). White dashed lines indicate 
cortical-medullary border based on UEA I staining (not shown). C, cortex; M, medulla. 
Scale bars 100µm. Analysis of images by histo-cytometry (bottom, left). Dots represent 
localization of each stain as determined by histo-cytometry. Frequency of CD86+ cells 
among CD11c+ cells identified as localized in the cortex by histo-cytometry (bottom, 
right). Number indicates percent cells in gated area. (C) Immunofluorescence 
microscopy (top) of thymic sections from C57BL/6 mice stained for F4/80 (green), and 
CD86 (red). White dashed lines indicate cortical-medullary border based on UEA I 
staining (not shown). C, cortex; M, medulla. Scale bars 100µm. Analysis of images by 
histo-cytometry (bottom, left). Dots represent localization of each stain as determined by 
histo-cytometry. Frequency of CD86+ cells among F4/80+ cells identified as localized in 
the cortex by histo-cytometry (bottom, right). Number indicates percent cells in gated 
area. Six- to twelve-week-old male and female mice were used. Data are representative 
of at least three independent experiments. 
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Figure 2.8 Immunofluorescence microscopy of CD80/CD86 KO thymus. 
 
(A) Immunofluorescence microscopy of thymic sections stained for DAPI (gray), UEA I 
(cyan), CD80 (magenta), and CD86 (red) in CD80/CD86 KO mice. C, cortex; M, 
medulla. Scale bars 100μm. (B) Immunofluorescence microscopy of thymic sections 
stained for DAPI (gray), UEA I (cyan), CD11c (green), and CD86 (red) in CD80/CD86 
KO mice. C, cortex; M, medulla. Scale bars 100μm. (C) Immunofluorescence 
microscopy of thymic sections stained for DAPI (gray), UEA I (cyan), F4/80 (green), and 
CD86 (red) in CD80/CD86 KO mice. C, cortex; M, medulla. Scale bars 100μm. Six- to 
twelve-week-old male and female mice were used. Data are representative of at least 
three independent experiments. 
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2.3 Discussion 
Defining the developmental stages and corresponding anatomic locations at 
which thymocytes undergo clonal deletion within the polyclonal repertoire has been 
challenging given current approaches. Here, we validated a cleaved caspase 3-based 
assay that can be used to examine clonal deletion at the population level. We made 
several observations regarding clonal deletion at distinct maturation stages in the 
thymus. Consistent with estimates that used other methods (67, 68), we observed that 
the majority of thymocytes underwent clonal deletion in the thymus cortex. However, 
thymocytes continued to undergo clonal deletion as they progressed through discrete 
maturation stages in the thymus medulla. Bone marrow-derived APC contributed to 
clonal deletion similarly in the thymus cortex and medulla. However, co-stimulatory 
molecule-mediated clonal deletion decreased as thymocytes emigrated from the cortex 
to the medulla. Thus, this approach served as a valuable tool to assess clonal deletion 
throughout thymocyte development. 
The degree of clonal deletion that occurs in the thymus cortex (78%) supports 
previous studies that the majority of clonal deletion occurs within the cortex (67, 68). 
This likely reflects the high propensity of TCRs to interact with MHC molecules, 
regardless of the specific peptide (67). Signaled thymocytes that are purged of the most 
cross-reactive TCRs go on to upregulate CCR7 and migrate to the medulla. Upon further 
analysis of clonal deletion within the thymus medulla, we observed apoptotic events at 
each of three distinct stages of maturation (107, 109). These findings are in contrast with 
a previous study that suggested that only semi-mature thymocytes were susceptible to 
clonal deletion (122). The discrepancies in these findings may lie in the use of different 
model systems. Kishimoto and Sprent utilized injection of TCR cross-linking antibodies 
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to observe thymocyte death ex vivo. However, such an approach induces extensive 
peripheral T cell activation, which can contribute to non-specific thymocyte death 
through the production of cytokines and glucocorticoid stress hormones (123, 124). To 
rule out non-specific deletion at these late stages of maturation, we utilized Nur77GFP 
reporter mice. GFP expression in deleted thymocytes was higher than non-deleted 
thymocytes at all three stages of maturation. Additionally, we showed that Treg and Treg 
precursors were enriched in apoptotic thymocytes at the most mature stages of 
development, supporting the notion that FOXP3 can act as a proapoptotic protein (111). 
These data therefore suggest that mature thymocytes indeed undergo TCR-induced 
apoptosis, which can involve FOXP3 induction as thymocytes reach their more mature 
developmental stage. 
We estimate that bone marrow APC contribute to approximately 40-45% of 
deletion events in both the thymus cortex and medulla. Previous studies estimated that 
50-70% of CD4SP thymocytes were deleted by bone marrow APC, based on CD4SP 
frequencies in MHC II-deficient bone marrow chimeras (44, 125). A more recent study, 
which based their estimates on high throughput analysis of the TCR repertoire in MHC 
II-deficient bone marrow chimeras, had a more conservative estimate of 30% of deletion 
events mediated by bone marrow APC (45). However, this study utilized a fixed TCRb, 
which may not fully reflect the WT TCR repertoire. Nonetheless, all of these data support 
the conception that bone marrow APC play a non-redundant role in mediating clonal 
deletion. 
We also showed a critical role for CD28-mediated co-stimulation in both the 
thymus cortex and medulla. The extent to which co-stimulation contributed to clonal 
deletion decreased as thymocytes emigrated from the cortex to the medulla. These 
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findings are in contrast with multiple studies involving superantigen or TCR-transgenic 
systems that did not find a requirement for CD28 in mediating clonal deletion (120, 126–
129). However, more recent studies did support a requirement for CD28 in superantigen-
mediated clonal deletion (119, 130). In one of these studies, Pobezinsky et al. showed 
that autoreactive DN thymocytes are diverted to an alternate CD8aa IELp in the 
absence of CD28-mediated co-stimulation (118, 119). Conversely, this diversion into 
agonist subsets was not observed at other stages of thymocyte development. Other 
agonist-selected cells – iNKT (DP stage) and Treg (CD4SP stage) – require CD28-
mediated co-stimulation for their survival and differentiation (113–117). It is unclear what 
signaling context distinguishes the various roles for CD28 in different thymocyte 
populations (120, 131). 
Surprisingly, our results also establish a non-redundant role for CD86 in 
mediating clonal deletion in the cortex. We do not yet understand if this is a qualitative 
role for CD86 in clonal deletion (i.e. CD86 allows the deletion of certain antigen-specific 
populations) or a quantitative requirement for a certain total level of co-stimulatory 
ligand. Regarding a qualitative role, we considered the possibility that a distinct CD80-
CD86+ antigen presenting cell subset was driving cortical clonal deletion. However, 
neither flow cytometric analysis nor immunofluorescence microscopy supported this 
hypothesis. Regarding a quantitative role, cortical thymocytes may require a higher total 
level of CD80/CD86 stimulation to trigger deletion. In this case, one would predict that 
either CD80 or CD86 deficiency would impact cortical deletion. 
In summary, we demonstrated that a cleaved caspase 3-based assay can be 
used to assess clonal deletion at the polyclonal level. This assay served as a valuable 
tool to study the location and stages of thymocyte development at which clonal deletion 
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occurs. We found that thymocytes undergo clonal deletion even at mature stages of 
development in the thymus medulla and that approximately half of deletion events 
require co-stimulation. We expect this assay may be useful in understanding the extent 
to which generalized clonal deletion defects contribute to autoimmunity caused by 
specific genetic mutations. 
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2.4 Materials and Methods 
2.4.1 Mice 
C57BL/6NCrl (B6) and B6.SJL-PtprcaPepcb/BoyCrl (B6.SJL) mice were purchased from 
Charles River Laboratories. C57BL/6Tg(Nr4a1-EGFP/cre)820Khog (Nur77GFP) and 
C57BL/6Tg(Rag2-EGFP)1Mnz (Rag2GFP) mice were described previously (105, 110). 
C57BL/6-Tg(Ins2-TFRC/OVA)296Wehi/WehiJ (RIP m-OVA), B6.Cg-
Tg(TcraTcrb)425Cbn/J (OT-II), B6.Cg-Ptprca Pepcb Tg(TcrLCMV)1Aox/PpmJ 
(SMARTA), B6.129S2-H2dlAb1-Ea/J (MHC II KO), B6.129S4-Cd80tm1Shr Cd86tm2Shr/J 
(CD80/CD86 KO), and B6.129S2-CD28tm1Mak/J (CD28 KO) were obtained from 
Jackson Laboratories. C57BL/6Foxp3tm2Ayr (FOXP3GFP) were kindly provided by M. A. 
Farrar (University of Minnesota) and were described previously (132). CD80floxBACTg/ 
B6.129S4-Cd80tm1Shr Cd86tm2Shr/J, referred to as CD86 KO mice in this study, were kindly 
provided by R. J. Hodes (National Institutes of Health) and were described previously 
(133). Bone marrow chimera mice were generated by reconstituting lethally irradiated 
(1,000 rads) mice with 107 T cell-depleted donor bone marrow cells. Recipient mice were 
provided with neomycin and polymyxin B supplemented water for at least 3 weeks 
following irradiation and bone marrow transplantation. Chimeras were analyzed at a 
minimum of six weeks after reconstitution. All animal experiments were approved by the 
Institutional Animal Care and Use Committee of the University of Minnesota. All animals 
were maintained under specific pathogen-free conditions at the University of Minnesota. 
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2.4.2 Flow Cytometry and MACS Purification 
Single-cell suspensions were stained for 30 minutes at 4º C with the indicated 
antibodies. Antibodies purchased from BioLegend: CD19 (6D5), CD25 (PC61), CD45.1 
(A20), CD45.2 (104), CD64 (X54-5/7.1), CD80 (16-10A1), CD90.1 (OX-7), NK1.1 
(PK136), TCRg/d (GL3), , TCRb (H57-597). Antibodies purchased from BD Biosciences: 
CD4 (GK1.5), CD8a (53-6.7), CD69 (H1.2F3), CD86 (GL1), CD90.2 (30-H12), H-2Kb 
(AF6-88.5), TCRb (H57-597). Antibodies purchased from Thermo Fischer: CD5 (53-7.3), 
MHC Class II– I-A/I-E (M5/114.15.2). Antibodies purchased from eBioscience: CD25 
(PC61.5), FOXP3 (NRRF-30). Staining for CCR7/CD197 (4B12; eBioscience) was 
performed for 30 minutes at 37ºC prior to additional surface stains. For cleaved 
caspase-3 (Asp175) (D3E9; Cell Signaling Technologies) staining: cells were processed 
as quickly as possible following harvest to avoid non-specific apoptosis. Following 
surface stain, cells were fixed with cytofix/cytoperm (BD Biosciences) for 30 minutes at 
4º C. Cells were then washed with perm/wash buffer (BD Biosciences) twice. Cells were 
stained with anti-cleaved caspase 3 at a 1:50 dilution for 30 minutes at 20º C. To isolate 
CD4SP thymocytes, we depleted DP and CD8SP thymocytes via negative enrichment 
using biotinylated anti-CD8a (53-6.7, eBioscience), Streptavidin MicroBeads (Miltinyi 
Biotec), and MACS separation columns (Miltinyi Biotec) per manufacturer’s protocol. 
Samples were acquired with BD LSR Fortessa X-20 (BD Biosciences) and analyzed with 
FlowJo version X (FlowJo LLC). 
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2.4.3 Immunofluorescence 
Thymi were harvested and snap frozen in Optimal Cutting Temperature compound 
(Sakura Finetek). 7µm sections were fixed and permeabilized in 100% acetone for 20 
minutes at 4º C. Samples were then blocked with 5% bovine serum albumin (BSA) and 
Fc block (anti-CD16/CD32; 2.4G2, Tonbo Biosciences) for one hour at 20ºC prior to 
staining. Antibodies were purchased from BD Biosciences: CD11c (HL3), BioLegened: 
F4/80 (BM8), CD86 (GL-1), Tonbo biosciences: CD80 (16-10A1), and Vector 
Laboratories: Fluorescein labeled Ulex Europaeus Agglutinin I (UEA I). Blocked sections 
were stained with desired antibodies combined into a cocktail in 0.5% BSA and 0.1% 
Tween-20 (Sigma Aldrich) overnight at 4ºC prior to DAPI staining. Sections were 
mounted using Prolong anti-fade mounting medium (Life Technologies). Images were 
acquired using a Leica DM6000B epifluorescent microscope 16-72 hours later. 
 
2.4.4 Histo-cytometry 
Histo-cytometry was performed as described previously, with modifications (134). Briefly, 
fluorochrome intensities of each region of interest (based on DAPI staining) were 
quantified using ImageJ. Data were exported into .csv format and imported into FlowJo 
for two-dimensional plotting. Medulla gates were drawn based on UEA I fluorescence 
intensity.  
 
2.4.5 Statistical Analysis 
Statistical analyses were performed using Prism 7 (GraphPad). Data sets were 
assessed for normality using D’Agostino & Pearson normality test. For comparison of 
  51 
two data sets, unpaired Student’s t test or unpaired Mann-Whitney test were performed. 
For comparison of three or more data sets, ordinary one-way ANOVA with Holm-Sidak’s 
or Tukey’s multiple comparisons test was used. P-values less than 0.05 were considered 
significant. Sample size, experimental replicates, and additional details are included in 
the figure legends. 
 
2.5 Publication 
This chapter has been modified (with permission) from the published article: 
Breed, E. R., Watanabe, M., & Hogquist, K. A. (2019). Measuring Thymic Clonal Deletion at the 
Population Level. The Journal of Immunology, 202(11), 3226-3233. 
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Chapter 3 
 
Defining the relative contribution of thymic APC subsets to 
central tolerance 
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3.1 Introduction 
A variety of antigen presenting cells (APC) in the thymus coordinate the selection 
of a T cell repertoire that is self-tolerant and effective against foreign pathogens. This 
selection process is dependent on the affinity of the T cell receptor (TCR) for self-
peptide–MHC presented by these APC, where strength of these interactions governs 
developing T cell fate. Weak interactions generate a naïve TCR repertoire via positive 
selection, whereas strong interactions can lead to clonal deletion and subsequent cell 
death by apoptosis. Regulatory T cell differentiation also occurs upon high-affinity TCR–
self-peptide–MHC interactions, but requires distinct cytokine and co-stimulatory signals 
(106, 115, 116). 
Thymic APCs include cortical and medullary thymic epithelial cells (cTEC and 
mTEC), thymic dendritic cells (DC), B cells, and mononuclear phagocytes (MNPs). Self-
peptides are presented by these APC subsets via multiple mechanisms. cTEC are 
specialized to present positively selecting ligands to developing double positive (DP) 
thymocytes. This is due, in part, to their ability to process and present self-peptides via 
machinery distinct from other thymic APC (112). mTEC are specialized for negative 
selection. The autoimmune regulator (AIRE) promotes presentation of tissue-restricted 
self-antigens (TRA) on both mTECs and B cells (60, 85, 135). These TRAs serve to 
reflect virtually all of the parenchymal organs within the thymus, thereby preventing 
dangerous autoreactive interactions after thymic clonal deletion and Treg cell induction 
(135). 
DC represent an exceptionally heterogeneous faction of thymic APC and also 
play a crucial role in processing and presenting self-peptides. Three major dendritic cell 
subsets have been described within the thymus. These subsets include plasmacytoid 
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DC (pDC) and two conventional DC (cDC) populations, which are delineated based on 
their expression of lineage defining cell surface markers and transcription factors (57, 
58). The two cDC subsets are comprised of XCR1+ (X-C chemokine receptor 1) cDC1, 
which cross-present TRAs acquired from mTEC, and SIRPa+ (signal regulatory protein 
alpha) cDC2, which are capable of circulating to the thymus and displaying self-antigen 
acquired from the periphery (1, 57, 59, 63, 136). Plasmacytoid DC (pDC) are also 
capable of acquiring self-peptide in the periphery for presentation in the thymus (65). 
The heterogeneity and distinct functional capabilities of these APC subsets 
suggest that there are non-redundant roles by which they mediate central tolerance. 
While each of these thymic APC subsets has been shown to be capable of mediating 
clonal deletion or Treg differentiation, many of these studies relied on model systems 
that are not representative of thymocyte selection in the polyclonal repertoire (137). 
These models include the use of endogenous superantigens, which do not imitate 
antigen-specific clonal deletion, and TCR transgenics, which due to the abundance of a 
single TCR and the timing at which the TCR is expressed during development, have a 
number of nonphysiologic consequences (97–102). Importantly, because of the 
strategies employed to study whether APC subsets mediate clonal deletion or Treg 
differentiation, their relative contribution to these processes is unknown. 
Given this, we sought to determine the extent to which different APC subsets in 
the thymus contribute to clonal deletion and nascent Treg differentiation in the polyclonal 
repertoire. Using a cleaved caspase-3 based assay to quantify clonal deletion in mice 
with APC-specific ablation or deficiency, we found that clonal deletion was not altered in 
the absence of B cells, pDC, XCR1+ cDC1, or MNPs. However, in an effort to eliminate 
SIRPa+ cDC2, we discovered that a fraction of this subset expresses the surface lectin, 
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CD301b. This subset required IL-4/IL-13 and was localized primarily within the thymus 
medulla. Mice lacking these DC had a measurable reduction in clonal deletion events, 
suggesting a non-redundant role for this subset in mediating clonal deletion.  
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3.2 Results 
3.2.1 Enumeration of thymic APC subsets 
As a whole, bone marrow APCs play a non-redundant role in mediating both 
clonal deletion and Treg selection (44, 45, 125, 137). To examine the relative 
contribution of distinct APC subsets to negative selection, we first sought to fully 
characterize and enumerate bone marrow APCs in adult (8-week-old) C57BL/6 mice 
(Figure 3.1A, Figure 3.2A and B). To determine the antigen presenting capability of 
these subsets, we assessed the expression of MHC II and the co-stimulatory molecules, 
CD80 and CD86 (Figure 3.1B and C). The conventional dendritic cell (cDC) subsets and 
B cells had the highest MHC II and cDC had the highest co-stimulatory molecule 
expression (Figure 3.1 B and C). Eosinophils, which are surprisingly abundant in the 
thymus, and neutrophils, which are more rare, expressed very little MCH II or CD86 
(Figure 3.1 B and C). In light of the relative MHC II and co-stimulatory molecule 
expression by these different APC subsets, we devised strategies to selectively deplete 
the APC subsets with the best antigen presenting potential (Figure 3.2C). There is 
currently no way to test a specific role for SIRPa+ cDC2s in mediating thymocyte 
negative selection due to lack of available depletion models. We therefore sought an 
alternative strategy by selectively targeting a subset of SIRPa+ cDC2s, which express 
the surface lectin, CD301b (macrophage galactose N-acetyl-galactosamine specific 
lectin 2; MGL2DTR-eGFP) (138). 
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Figure 3.1. Enumeration of thymic APC subsets.  
 
(A) Numbers of antigen presenting cell subsets (gated as in Supplementary Figure 1A, 
B) in 8-week-old mice. (B) Representative flow cytometry histograms showing 
expression of MHC II (left), CD80 (middle), and CD86 (right) by the indicated antigen 
presenting cell subset (gated as in Figure 3.2 A, B). (C) MHC II (left), CD80 (middle), 
and CD86 (right) gMFI (normalized to controls) of antigen presenting cell subsets. Each 
symbol (A, C) represents an individual mouse. Eight to nine-week-old female mice were 
used. Small horizontal lines indicate the mean, and error bars represent SEM. Data are 
pooled from three (A) or one (C) independent experiments or are representative of at 
least three independent experiments (B). 
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Figure 3.2. Comprehensive gating strategy to identify thymic APC subsets.  
 
(A) Flow cytometry gating strategy for identifying B cells and dendritic cell subsets. B 
cells were identified by the expression of CD19 and B220 (blue; top, middle). 
Plasmacytoid DC were identified by the expression of B220, CD11c, and PDCA-1 
(CD317) (salmon; bottom, middle). Conventional dendritic cells were identified by the 
expression of MHC II and CD11c (top, middle right). cDC1 were identified by the 
expression of XCR1 (magenta) and cDC2 identified by the expression of SIRPa (teal; 
top, right). CD301b+ cDC2 were identified by the expression of CD301b (green; bottom, 
right). (B) Flow cytometry gating strategy for identifying eosinophils, neutrophils, and 
MNPs. Eosinophils were identified by the expression of Siglec F (orange) and 
neutrophils were identified by the expression of Ly6G (1A8) (pink; middle right). MNPs 
were identified by the expression of FcgR1 (CD64) (purple; right). (C) Mouse strains 
utilized to target each APC subset. Data are representative of more than 10 independent 
experiments (A, B). 
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3.2.2 CD301b is expressed by a large proportion of SIRPa cDC in the 
thymus 
To determine if MGL2DTR-eGFP mice could be used as a model to selectively 
deplete a proportion of thymic SIRPa+ cDC2, we first evaluated the expression of 
CD301b on SIRPa+ cDC2. As previously reported, CD301b was expressed by a subset 
of SIRPa+ cDC2 in the skin draining lymph nodes (sdLN), but not the spleen (Figure 
3.3A and B) (138, 139). Surprisingly, an even larger proportion (~45%) of SIRPa+ cDC2 
expressed CD301b in the thymus (Figure 3.3A and B). It has been shown that CD301b+ 
dermal dendritic cells mediate type 2 immune responses (138, 140–142). To determine if 
thymic CD301b+ cDC2 were responsive to type 2 cytokines, we analyzed the expression 
of CD301b on SIRPa+ cDC2 in mice lacking IL-4 (IL-4 KO) or the shared receptor for IL-
4 and IL-13 (IL-4Ra KO). In the absence of IL-4, the frequency of CD301b+ SIRPa+ 
cDC2 decreased by half (Figure 3.3C and D). And in the absence of IL-4R, they were 
completely absent, suggesting that thymic CD301b cDC2 require type 2 cytokines 
(Figure 3.3C and D). Because thymic invariant natural killer T (iNKT) cells are the 
primary source of thymic IL-4 in the steady state, we sought to determine if CD301b 
expression was dependent, at least in part, on IL-4 provided by iNKT cells. We therefore 
examined CD301b expression in mice lacking iNKT cells (CD1d KO). As expected, 
similar to IL-4 KO mice, the expression of CD301b on SIRPa+ cDC2 was decreased by 
nearly half (Figure 3.3C and D). 
Previous work from our lab demonstrated that there is an age-dependent 
skewing of iNKT subsets, in which NKT2 cells represent a higher proportion of iNKT 
subsets early in life, but decline in adulthood (143). This suggests that steady state IL-4 
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production in the thymus is highest early in life. It has also been shown that the 
proportion of SIRPa+ cDC2 increases from birth to 4 weeks of age in NOD mice (73). To 
test if this temporal fluctuation in IL-4 production impacted CD301b expression by 
SIRPa+ cDC2, we examined thymic APC in C57BL/6 mice at various ages (Figure 3.3E, 
Figure 3.4). CD301b on SIRPa+ cDC2 was similar at all ages (Figure 3.3E). Consistent 
with previous reports, there was a modest increase in SIRPa+ cDC2 with age (Figure 
3.4C) (73). Accordingly, the frequency of CD301b+ SIRPa+ cDC2 increased with age as 
well (Figure 3.3D). 
Because IL-4-producing NKT2 are concentrated within the thymus medulla (12; 
data not shown), we sought to determine the localization of CD301b-expressing cells. 
Indeed, CD301b expression in the thymus was localized primarily within the thymus 
medulla (Figure 3.3F), further supporting the notion that thymic NKT2 support this subset 
of cDC. 
Previous studies suggested that XCR1+ cDC1 are tissue resident, whereas 
SIRPa+ cDC2 can circulate (57). To gain insight into what fraction of CD301b+ SIRPa+ 
cDC2 circulate, we generated parabiotic mice, which through the joining of vasculature 
share blood circulation (Figure 3.3G). Congenically distinct CD45.1+ and CD45.2+ mice 
were surgically conjoined for 30 days. Consistent with known circulation patterns, naïve 
CD8 T cells equilibrated in parabiotic pairs (Figure 3.3H). >95% of XCR1+ cDC1 were of 
host origin, verifying that this subset does not circulate (Figure 3.3H). However, ~90% of 
SIRPa+ cDC2 were also of host origin, indicating that while this subset may be more 
migratory than XCR1+ cDC1, SIRPa+ cDC2 are predominately tissue resident (Figure 
3.3H). There was no difference in circulation between CD301b- and CD301b+ SIRPa+ 
cDC2, suggesting that these subsets have similar migratory patterns (Figure 3.3H). 
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Figure 3.3. CD301b+ SIRPa+ DC were enriched in the thymus compared to 
peripheral SLO and localized in the thymus medulla.  
 
(A) Representative flow cytometry of XCR1+ and SIRPa+ cDC (top) and CD301b+ DC 
(bottom) from spleen (bottom), pooled sdLN (middle), and thymus (right) from C57BL/6 
mice. Numbers adjacent to outlined areas represent percent cells in each. (B) Frequency 
of CD301b+ among SIRPa+ DC in spleen, sdLN, and thymus from C57BL/6 mice. (C) 
Representative flow cytometry of XCR1+ and SIRPa+ cDC (top) and CD301b+ DC 
(bottom) from Balb/c.BYJ (left), IL-4 KO (middle left), IL-4Ra KO (middle right), and 
CD1d KO (right) mice. Numbers adjacent to outlined areas represent percent cells in 
each. (D) Frequency of thymic CD301b+ among SIRPa+ cDC2 in Balb/c.BYJ, IL-4 KO, 
IL-4Ra KO, and CD1d KO mice. (E) Frequency of thymic CD301b+ among SIRPa+ DC in 
2d, 1w, 2w, 3w, and 8w-old C57BL/6 mice. (F) Immunofluorescence microscopy (top) of 
thymic sections from C57BL/6 mice stained for CD11c (red) and CD301b (green). White 
dashed lines indicate cortical-medullary border based on UEA I staining (not shown). C, 
cortex; M, medulla. Scale bars 100µm. Analysis of images by histo-cytometry (bottom, 
left). Dots represent localization of each stain as determined by histo-cytometry. 
Frequency of CD301b+ cells identified as localized in the cortex by histo-cytometry 
(bottom, right). Numbers indicate percent cells in each outlined area. (G) Experimental 
strategy for generating parabiotic mice. (H) Frequency of cells derived from the host 
parabiont amongst splenic CD8 T cells, thymic SIRPa+ cDC2, thymic CD301b+ cDC2, or 
thymic XCR1+ cDC1. Each symbol (B, D, E, H) represents an individual mouse. Six to 
twelve-week-old male and female mice were used. Small horizontal lines indicate the 
mean and error bars represent SEM. Data are representative of at least three 
independent experiments (A, C, F), pooled from at least three independent experiments 
(B, D), pooled from one or two independent experiments (E), or are from one experiment 
(H). 
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Figure 3.4. Ontogeny of thymic APC subsets.  
 
(A-I) Frequency of thymic APC subsets (as indicated) among total lymphocytes in 2d, 
1w, 2w, 3w, and 8w-old C57BL/6 mice (as in Supplementary Figure 1A, B). Each symbol 
represents an individual mouse. Male and female mice were used. Small horizontal lines 
indicate the mean and error bars represent SEM. Data are pooled from one, two, or 
three independent experiments. 
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3.2.3 Distinguishing APC influence on nascent Treg generation 
Previous studies have suggested distinct roles for various APC subsets in 
mediating the differentiation of Treg (112), however these studies did not distinguish 
between nascent Treg undergoing selection in the thymus and recirculating Treg. 
Because about half of CD25+FOXP3+ mature Treg (mTreg) (Figure 3.5A) represent 
recirculating cells (110) (Figure 3.5B), we sought to identify cell surface markers to 
distinguish nascent from recirculating mTreg. To differentiate nascent and recirculating 
cells, we first utilized RAG2GFP mice, in which GFP decay acts as a “molecular timer” 
from positive selection (110). In line with a recent study, CD73 in combination with 
various markers (CD44, CCR7, and neuropilin 1 (NRP1)) could distinguish between 
nascent and recirculating mTreg (Figure 3.5C) (144, 145). Over 90% of CD73- mTreg 
were RAG2GFP+ and over 85% of CD73+ mTreg were RAG2GFP- (Figure 3.6A). Further 
analysis revealed that CD73 in combination with CD44, CCR7, or NRP1 could ideally 
distinguish between nascent and recirculating CD4+ T cells in the thymus (Figure 3.6B 
and C). 
To determine the individual contribution of distinct APC subsets to the generation 
of mTreg, we evaluated the thymic development of mTreg in mice with selective APC 
deficiencies (Figure 3.2C).  These strategies showed >85% depletion efficiency (Figure 
3.7). We also examined AIRE-deficient (AIRE KO) animals, which had a 50% reduction 
in mTreg (Figure 3.5 D), as previously reported. Also consistent with previous reports, 
animals lacking B cells had a reduction in mTreg (Figure 3. 5 D) (86, 95). The mTreg 
pool was not affected in the absence of any of the three individual DC subsets or in mice 
lacking MHC II on MNPs (Figure 3.5 D). We chose to selectively knockout MHC II on 
MNPs in contrast to selective depletion because the thymus atrophies acutely in mice 
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after diphtheria toxin depletion in LysMCre-Csf1rLsL-DTR mice (data not shown) (146). To 
broaden our analysis, we evaluated nascent and recirculating mTreg in these animals. 
AIRE KO animals had a reduction in both nascent and recirculating mTreg (Figure 3.5E), 
suggesting that AIRE directly influences the size of the mTreg pool selected. However, B 
cell KO mice only had a reduction in recirculating mTreg, indicating that B cells do not 
affect the size of the selected Treg pool in the thymus, but that B cells may be important 
for the maintenance or trafficking of mTreg in the periphery (Figure 3.5F) (147). Neither 
the DC subsets nor MNPs impacted the size of the nascent or recirculating mTreg pool 
(Figure 3.8). 
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Figure 3.5. Individual APC subset deficiency did not impact the size of the nascent 
mTreg pool.  
 
(A) Flow cytometry gating strategy for identifying mature Treg. (B) Flow cytometry of 
mature Treg from RAG2GFP mice. Recirculating mTreg were identified as GFP- (black 
outline) and nascent mTreg are GFP+ (green outline). Numbers adjacent to outlined 
areas indicate percent cells in each. (C) Surface staining of CD73, CD44, CCR7, and 
NRP1 on RAG2GFP- (recirculating; gray) or RAG2GFP+ (nascent; green) mTreg (as gated 
in Figure 3.5A). (D) Frequency of mTreg among TCRb+ CD4 T cells (as gated in Figure 
2A) in mice with selective APC deficiencies (as labeled). (E) Frequency of nascent (left) 
or recirculating (right) mTreg among TCRb+ CD4 T cells in AIREWT or AIREKO mice, 
based on expression of CD73 and CD44 (as in Figure 3.6A; top left). (F) Frequency of 
nascent (left) or recirculating (right) mTreg among TCRb+ CD4 T cells in Mb1WT or 
Mb1Cre+/+ mice, based on expression of CD73 and CD44 (as in Figure 3.6A; top left). 
Each symbol (D, E, F) represents an individual mouse. Six to twelve-week-old male and 
female mice were used. Small horizontal lines indicate the mean and error bars 
represent SEM. **P< 0.01, ***P< 0.001, ****P< 0.0001. Statistical significance was 
determined by Mann-Whitney test (D, E, F). Data were pooled from at least three 
independent experiments (D, E, F) or are representative of at least three independent 
experiments (A, B, C). 
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Figure 3.6. Identifying nascent and recirculating CD4 T cells. 
 
(A) Gating strategy for identifying recirculating (gray) and nascent (green) mTreg based 
on CD73, CD44, CCR7, and NRP1 expression (top) and GFP expression (RAG2GFP) of 
the indicated gate (bottom). Numbers adjacent to the outlined areas represent percent 
cells that are GFP- (gray) or GFP+ (green) from the correlating gates (top). (B) Surface 
staining of CD73, CD44, CCR7, and NRP1 on RAG2GFP- (recirculating; black) or 
RAG2GFP+ (nascent; green) TCRb+ CD4 T cells. (C) Gating strategy for identifying 
recirculating (gray) and nascent (green) TCRb+ CD4 T cells based on CD73, CD44, 
CCR7, and NRP1 expression (top) and GFP expression (RAG2GFP) of the indicated gate 
(bottom). Numbers adjacent to the outlined areas represent percent cells that are GFP- 
(gray) or GFP+ (green) from the correlating gates (top). Six to twelve-week-old male and 
female mice were used. Data are representative of at least three independent 
experiments. 
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Figure 3.7. APC subset depletion efficiency.  
 
(A) Representative flow cytometry plots of B220+CD19+ B cells from Mb1WT (left) and 
Mb1Cre+/+ (right) mice. Numbers adjacent to outlined areas represent percent cells in 
each. (B) Representative flow cytometry plots of XCR1+ and SIRPa+ DC from BATF3WT 
(left) and BATF3KO (right) mice. Numbers adjacent to outlined areas represent percent 
cells in each. (C) Experimental strategy for selective depletion of CD301b+ DC 
(MGL2DTR) or pDC (BDCA2DTR). (D) Representative flow cytometry plots of 
CD11c+PDCA1+ pDC from diphtheria toxin treated pDCWT (left) or pDCDTR+/- (middle) 
mice (Figure 3.7C), and frequency of pDC among lymphocytes after diphtheria toxin 
treatment (right). Numbers adjacent to outlined areas represent percent cells in each. (E) 
Representative flow cytometry plots of XCR1+ and SIRPa+ DC from MGL2WT (top left) or 
MGL2DTR+/- (top middle) mice (as in Figure 3.2A) and frequency of SIRPa+ DC among 
cDC after diphtheria toxin treatment (top right). Representative flow cytometry plots of 
CD301b+ SIRPa+ DC from MGL2WT (bottom left) or MGL2DTR+/- (bottom middle) mice (as 
in Figure 3.7C), and frequency of CD301b+ among SIRPa+ DC after diphtheria toxin 
treatment (bottom right). Numbers adjacent to outlined areas represent percent cells in 
each. (F) Representative flow cytometry histograms showing expression of MHC II on 
thymic APC subsets (top) and MHC II gMFI (bottom) from littermate control or LysMCre+/-
IAbfl/fl mice. Each symbol (D, E, F) represents an individual mouse. Six to twelve-week-
old male and female mice were used. Small horizontal lines indicate the mean and error 
bars represent SEM. ***P< 0.001, ****P< 0.0001. Statistical significance was determined 
by Mann-Whitney test (D, E). Data are representative of at least three independent 
experiments (A, B), or are pooled from three independent experiments (D, E), or one 
experiment (F). 
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Figure 3.8. Nascent and recirculating Treg in APC deficient mice. 
 
(A-D) Frequency of nascent (left) or recirculating (right) mTreg among TCRb+ CD4 T 
cells based on expression of CD73 and CD44 (as in Figure 3.6A; top left) in (A) pDCWT 
or pDCDTR+/- mice (as in Supplementary Figure 5C, D), (B) BATF3WT or BATF3KO mice, 
(C) MGL2WT or MGL2DTR+/- mice (as in Figure 3.7C, E), or (D) littermate control or 
LysMCre+/-IAbfl/fl mice. Each symbol represents an individual mouse. Six to twelve-week-
old male and female mice were used. Small horizontal lines indicate the mean and error 
bars represent SEM. Statistical significance was determined by Mann-Whitney test. Data 
are pooled from two (A, B), three (C), or one independent experiments (D). 
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3.2.4 CD301b+ SIRPa+ cDC play a non-redundant role in mediating clonal 
deletion 
While several APC subsets, including XCR1+ cDC1, pDC, and B cells, have been 
shown to be capable of mediating clonal deletion, most of these studies utilized TCR 
transgenic models (112). To address this, we examined clonal deletion at the population 
level using a cleaved caspase 3-based assay in each APC-deficient strain (Figure 3.2C) 
(148). Total CD4 numbers in these strains were the same as their wild-type controls 
(Figure 3.9A). As expected, AIRE KO animals had a reduction (~33%) in clonal deletion 
of medullary CD4 T cells (Figure 3.10A; left). These animals also had a modest 
reduction in clonal deletion of cortical thymocytes (Figure 3.9B). We did not observe a 
distinct role for B cells, pDC, XCR1+ cDC, or MNPs in mediating clonal deletion at the 
population level (Figure 3.10A). However, after a 10-day depletion of CD301b+ SIRPa+ 
cDC2 (Figure 3.7C), clonal deletion of medullary CD4 T cells was reduced by 
approximately 20%, suggesting a non-redundant role for CD301b+ SIRPa+ cDC2 in 
facilitating clonal deletion (Figure 3.10A; middle right). In line with the medullary 
localization of this CD301b+ cDC2 subset, cortical clonal deletion was not affected 
(Figure 3.9B). 
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Figure 3.9. Enumeration of thymocytes and cortical clonal deletion in mice with 
selective APC deficiency.  
 
(A) Total CD4 T cells in mice with selective APC deficiencies (as labeled). (B) Frequency 
of CD5+ TCRb+ cleaved caspase 3+ thymocytes among DP T cells in mice with selective 
APC deficiencies (as labeled). Each symbol represents an individual mouse. Six to 
twelve-week-old male and female mice were used. Small horizontal lines indicate the 
mean and error bars represent SEM. *P< 0.05. Statistical significance was determined 
by Mann-Whitney test. Data are pooled from at least three independent experiments. 
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To further confirm that CD301b+ SIRPa+ cDC2 were capable of mediating clonal 
deletion, we utilized an eGFPp–I-Ab tetramer to detect CD4 T cells specific for the model 
self-antigen, eGFP (42). To test tolerance to eGFP, we immunized MGL2DTR-eGFP mice or 
WT littermate controls with eGFPp in complete freunds adjuvant (CFA). Magnetic 
enrichment for tetramer-bound cells from pooled secondary lymphoid organs was 
employed to directly measure total numbers of eGFPp–I-Ab–specific CD4 T cells. 
Immunized MGL2DTR-eGFP mice had fewer than 100 eGFPp–I-Ab–specific CD4 T cells 
(50-fold fewer than WT controls) (Figure 3.10B and C). Additionally, very few FOXP3+ 
Treg (Figure 3.10D and E) or CXCR5+ T follicular helper cells (Tfh) (Figure 3.10F and G) 
were observed in these mice. These numbers are suggestive of intrathymic deletion or 
“cluster 3 tolerance” proposed by Malhotra et al. (42). This is in contrast to the 
alternative tolerance mechanisms– ignorance (cluster 1) or partial clonal deletion with 
enhanced Treg potential (cluster 2) put forward by this group (42). Interestingly, only 8% 
of cDC were I-Ab+ eGFP+ in MGL2DTR-eGFP mice (Figure 3.11). This percentage was lower 
than those observed in other cluster 3 mouse strains (ItgaxeYFP and ACTBeGFP) by 
Malhotra et al., indicating that while the total number of APC presenting cell expressing a 
particular self-antigen may be important, the APC subset presenting the self-antigen 
may also play an critical role in determining the tolerance mechanism enforced (42). 
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Figure 3.10. CD301b+ SIRPa+ cDC play a non-redundant role in clonal deletion. 
 
(A) Frequency of CD5+ TCRb+ cleaved caspase 3+ thymocytes among CCR7+ CD4 T 
cells in mice with selective APC deficiencies (as labeled). (B) Representative flow 
cytometry analyzing eGFPp–IAb–PE and eGFPp–IAb–APC staining of tetramer-enriched 
CD4 T cells from pooled spleens and lymph nodes of MGL2WT and MGL2DTR 10 days 
after immunization with 100µg eGFPp emulsified with CFA. (C) Total eGFPp–IAb–
tetramer-binding CD4 T cells (as in Figure 3B). (D) Representative flow cytometry of 
CD25 and FOXP3 expression among eGFPp–IAb–tetramer-binding CD4 T cells 
identified in B. (E) Total FOXP3+ cells among eGFPp–IAb–tetramer-binding CD4 T cells. 
(F) Representative flow cytometry of PD1 and CXCR5 expression among eGFPp–IAb–
tetramer-binding CD4 T cells identified in B. (E) Total CXCR5+ cells among eGFPp–IAb–
tetramer-binding CD4 T cells. Each symbol (A, C, E, G) represents an individual mouse. 
Six to twelve-week-old male and female mice were used. Small horizontal lines indicate 
the mean and error bars represent SEM. *P< 0.05, **P< 0.01, ***P< 0.001. Statistical 
significance was determined by Mann-Whitney test (A, C, E, G). Data are pooled from at 
least three independent experiments. 
 
 
 
 
 
 
Figure 3.11. eGFP expression by cDC in MGL2DTR-eGFP mice. 
 
(A) Representative flow cytometry of MHC II+ CD11c+ cDC (left) and MGL2-eGFP 
expression on SIRPa+ cDC (right). Numbers adjacent to outlined areas represent 
percent cells in each. Six to twelve-week-old male and female mice were used. Data are 
representative of at least three independent experiments. 
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3.3 Discussion 
Developing thymocytes encounter self-peptide–MHC on an assortment of APCs 
with distinct functional capabilities in order to generate self-tolerance. Although a number 
of previous studies demonstrated contributions of each subset to clonal deletion or Treg 
cell differentiation, the relative extent to which each APC enforces these self-tolerance 
mechanisms remained unclear. Here, we took a comprehensive approach to investigate 
the role of distinct APC subsets to clonal deletion or Treg cell generation at the 
population level. 
While no studies collectively enumerated the different bone marrow-derived APC 
in the thymus, our analysis is in line with previous estimates of the relative proportion of 
these subsets. The three DC subsets– XCR1+ cDC1, SIRPa+ cDC2, and pDC– were 
equally represented in the thymus (1, 57, 65), each constituting approximately 1x105 
cells in an adult C57BL/6 mouse. B cells were similarly proportionate compared to the 
combined DC subsets (1), totaling 4x105 cells. The other myeloid subsets are less well 
described in the thymus.  Surprisingly, eosinophils were quite abundant, comprising 
5x105 cells, a proportion equal to that of B cells. MNPs represented a fraction similar to 
that of the individual DC subsets (1x105 cells), while neutrophils constituted only one-
sixth of these populations.  
Previous work from our group and others demonstrated that both MHC II and co-
stimulatory molecule expression are critical for Treg development and clonal deletion 
(44, 45, 113, 115–117, 125, 137). Here, we showed that the cDC subsets and B cells in 
the thymus are particularly well equipped to promote tolerance via these mechanisms 
because of their high MHC II and co-stimulatory molecule expression. In contrast, 
eosinophils, while abundant did not express MHCII or co-stimulatory molecules. 
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Combined, the relative proportion and antigen presenting capabilities of particular 
subsets suggests that they could be superior at enforcing central tolerance when 
compared to other thymic APC. 
The role of AIRE in mediating Treg cell differentiation at the population level has 
been somewhat controversial. It was initially reported that there is no defect in Treg cell 
development in adult AIRE-deficient mice (32, 40, 149), however others have 
demonstrated a nearly 50% defect in adult and particularly in neonatal mice (49, 59). 
Additionally, analysis of the Treg cell TCRa repertoire in AIRE-deficient mice showed 
clear differences, revealing that AIRE plays a critical role in selecting the Treg cell 
repertoire (45, 51). Here, we report a 50% reduction in the frequency of both nascent 
and recirculating mTreg cells in the thymus of AIRE deficient adult mice. While the 
reasons for these conflicting reports are unclear, the defect that we observed may be 
due to our analysis of collectively younger adult mice (49, 52). 
It is assumed that clonal deletion is a major mechanism by which AIRE enforces 
central tolerance. Several landmark studies showed that mTECs can facilitate clonal 
deletion of TRA-specific TCR transgenic thymocytes (40, 41). More recently, through the 
use of tetramer enrichment, it was shown that polyclonal TRA-specific T cells were 
modestly increased in the absence of AIRE (42). Indeed, we observed a 33% reduction 
in medullary CD4+ thymocytes undergoing clonal deletion in AIRE-deficient mice 
compared to their WT counterparts. Surprisingly, we also noted a mild defect in cortical 
(CCR7- thymocyte) clonal deletion in mice lacking AIRE. This suggests that some 
thymocytes may contact MHCII+ mTEC, cDC1, or B cells (the major APC that present 
AIRE dependent self-antigens) prior to expression of CCR7, although further work would 
be required to test this definitively. 
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We showed that while B cell deficiency certainly impacts the size of the mTreg 
cell pool, B cells may not have as great an impact on nascent mTreg cell development 
as previously thought (86, 95). Using CD73 in combination with CD44 to identify 
recirculating mTreg cells, we demonstrated that systemic B cell deficiency primarily 
impacted the recirculating mTreg cell pool in the thymus. Because recirculating mTreg 
cells represent nearly 50% of the total thymic mTreg cells (110), this population may 
have skewed the findings in previous studies (86, 95). Interestingly, Ray et al. found that 
GITR-GITRL signaling in between T and B cells in peripheral lymphoid organs was 
required for peripheral Treg cell maintenance (147), which may explain our findings 
here. While several studies showed that B cells are capable of mediating clonal deletion 
either using endogenous superantigens or TCR transgenic models (85, 87, 89, 91, 92), 
we did not identify a non-redundant role for B cells in mediating clonal deletion at the 
population size level. However, this does not rule out that thymic B cell deficiency may 
have altered the Treg cell TCR repertoire. 
pDC, XCR1+ cDC1, and MNPs were dispensable for both mTreg cell 
development and clonal deletion at the population size level as well. pDC are capable of 
promoting Treg cell differentiation in vitro (81), however their role in Treg cell 
development in vivo was unclear. OVA-loaded pDC were shown to mediate clonal 
deletion, but not Treg cell development, of OT-II thymocytes. However, this model 
system may reflect the high-affinity TCR–pMHC interaction more than a physiologic role 
for pDC in mediating central tolerance. Our findings that XCR1+ cDC1 do not impact 
Treg cell differentiation or clonal deletion are in line with previous work that 
demonstrated that BATF3-deficient mice had a modest increase in the proportion of 
thymic Treg cells and no difference in the Treg cell TCR repertoire (80). This group also 
  79 
used deep TCR sequencing to determine that XCR1+ cDC1 do not mediate clonal 
deletion of CD8+ thymocytes (71). Thymic MNPs are critical for clearing apoptotic debris 
(150, 151), however whether they contribute to thymocyte negative selection remained 
unclear. Here, we did not find a non-redundant role for MNPs in mediating either clonal 
deletion or mTreg cell differentiation. More work will be necessary to determine how 
thymic MNPs impact the TCR repertoire. Collectively, our findings suggest functional 
redundancy for pDC, XCR1+ cDC1, and MNPs in mediating central tolerance at least at 
the population size level. 
Alternatively, our results did establish a non-redundant role for SIRPa+ cDC2 in 
clonal deletion at the population size level. Although there is currently no method to 
selectively target all SIRPa+ cDC2, we found that nearly half of thymic SIRPa+ cDC2 
express CD301b, which could be depleted using MGL2DTR-eGFP mice (138). Depletion of 
CD301b+ SIRPa+ cDC2 led to a 20% reduction in the size of the clonal deleted 
population.  Why depleting this DC subset had a detectable effect, while depleting any 
other APC subset did not, is currently unclear.  Interestingly, CD301b expression was 
enriched on thymic SIRPa+ cDC2 compared to SIRPa+ cDC2 in secondary lymphoid 
organs. We demonstrated that these CD301b-expressing SIRPa+ cDC2 were dependent 
on the type 2 cytokine-enriched thymic environment that our group has shown is largely 
established by thymus tissue resident NKT2 cells that produce IL-4 at steady state (143). 
How these type 2 cytokine-dependent SIRPa+ cDC2 differentially impact tolerance 
induction compared to other SIRPa+ cDC2 will require development of additional tools 
(84). However, DC have been shown to be capable of mediating Treg cell selection in 
TCR transgenic models and in vitro (76, 78, 79), leaving the possibility that the 
remaining SIRPa+ cDC2 in our system could promote Treg cell differentiation. 
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In summary, our comprehensive analysis of thymic APC and their ability to 
induce either clonal deletion or Treg cell differentiation provides insight into the 
differential tolerance mechanisms promoted by these subsets. AIRE unequivocally had 
the greatest relative impact on both Treg cell development and clonal deletion. However, 
we identified a subset of SIRPa+ cDC2 that was dependent on type 2 cytokine signaling 
and played a non-redundant role in mediating clonal deletion. Given the profound impact 
of type 2 cytokines on this CD301b+ SIRPa+ cDC2 subset and the effect that this subset 
had enforcing central tolerance, it is interesting to consider the influence that a type 2 
cytokine-enriched environment has on generating a self-tolerant TCR repertoire. 
Perhaps IL-4 and IL-13 impact the thymic APC peptidome to induce tolerance to type 2 
cytokine-dependent processes in the periphery, such as wound healing and the 
inflammatory response to helminth infections (152). Whether the functional preference of 
this CD301b+ SIRPa+ cDC2 for clonal deletion is due to superior antigen presenting 
capability via increased MHC II and co-stimulatory molecule expression or a unique 
peptidome will be the work of future studies. 
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3.4 Materials and Methods 
Mice 
C57BL/6NCrl (B6) and B6.SJL-PtprcaPepcb/BoyCrl (B6.SJL) mice were purchased from 
Charles River Laboratories. C57BL/6Tg(Rag2-EGFP)1Mnz (Rag2GFP) mice were 
described previously (110). B6.129S2-Airetm1.1Doi/J (AIRE KO), B6.C(Cg)-
Cd79atm1(cre)Reth/EhobJ (Mb1Cre), C57BL/6-Tg(CLEC4C-HBEGF)956Cln/J (pDCDTR), 
B6.129S(C)-Batf3tm1Kmm/J (BATF3 KO), B6(FVB)-Mgl2tm1.1(HBEGF/EGFP)Aiwsk/J (MGL2DTR), 
B6.129P2-Lyz2tm1(cre)Ifo/J (LysMCre), B6.129X1-H2-Ab1tm1Koni/J (IAbfl/fl), BALB/cByJ, and 
C.129S2-Cd1tm1Gru/J (CD1d KO) were purchased from Jackson Laboratories. BALB/c 
Il4tm1(CD2)Mmrs (IL-4 KO) and BALB/c Il4ratm1Fbb (IL-4Ra KO) were described 
previously (143). All animal experiments were approved by the Institutional Animal Care 
and Use Committee of the University of Minnesota. All animals were maintained under 
specific pathogen-free conditions at the University of Minnesota. 
 
Parabiosis Surgery  
Parabiosis surgeries were performed as previously described (153). Briefly, mice were 
anesthetized with ketamine. Flank hair was shaved and then further removed using Nair. 
Lateral incisions were made and mice were joined with interrupted horizontal mattress 
sutures with 5–0 NOVAFIL. Additional sutures were placed through the olecranon and 
knee joints to secure the legs. Parabiotic pairs were analyzed 30 days after surgeries. 
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Diphtheria Toxin Treatment 
pDCDTR, MGL2DTR, and littermate control mice were injected intraperitoneally with 
diphtheria toxin every 48 hours for 9 days (5 injections in total). The first injection 
contained 500ng diphtheria toxin in 100µL PBS; the following injections contained 100ng 
diphtheria toxin in 100µL PBS. Mice were analyzed the day after the final injection. 
 
Immunization 
Mice were given subcutaneous and intraperitoneal injection of 100µL CFA emulsion 
(Sigma-Aldrich) containing 100µg peptide (described below) in DMSO split over two 
sites. 
 
Tetramers and Cell Enrichment and Flow Cytometry 
Biotin-labeled I-Ab monomers containing eGFP peptide (HDFFKSAMPEGYVQE) 
covalently linked to the I-Ab b-chain were purified and combined with streptavidin- PE or 
streptavidin- APC (Prozyme) to produce fluorescence-labeled I-Ab tetramers as 
described previously (42). 
Single cell suspensions were prepared from pooled spleen and lymph nodes 
(inguinal, axillary, brachial, cervical, para-aortic, and mesenteric). Cells were stained for 
1h at room temperature with PE- and APC-conjugated tetramers and anti-CXCR5 (2G8, 
BD). PE and APC MicroBeads (Miltinyi Biotec) and MACS separation columns (Miltinyi 
Biotec) were utilized for enrichment as previously described (154). 
Single-cell suspensions were stained for 30 minutes at 4º C with the indicated 
antibodies (below). Staining for CCR7/CD197 (4B12; eBioscience) was performed for 30 
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minutes at 37ºC prior to additional surface stains. Cleaved caspase-3 (D3E9; Cell 
Signaling Technologies) staining was described previously (148).  
For thymic APC populations, thymi were first injected with 500µL Collagenase D 
(1mg/mL; Roche), then finely chopped in 1mL Collagenase D, and incubated for 30 
minutes at 37ºC. Single cell suspensions were then prepared and stained as indicated.  
Samples were acquired with BD LSR Fortessa X-20 (BD Biosciences) and 
analyzed with FlowJo version X (FlowJo LLC). 
 
Antibodies 
Antibodies purchased from BioLegend: NK1.1 (PK136), CD11c (N418), CD19 (6D5), 
CD25 (PC61), TCRg/d (GL3), CD80 (16-10A1), CD64 (X54-5/7.1), CD45.1 (A20), 
CD45.2 (104), CD45R (B220; RA3-6B2), CD90.1 (OX-7), CD172a (SIRPa; P84), 
CD301b (MGL2; URA-1), CD317 (PDCA-1, BST2; 129C1), F4/80 (BM8), TCRb (H57-
597), XCR1 (ZET). 
 
Antibodies purchased from BD Biosciences: CD4 (GK1.5), CD8a (53-6.7), CD69 
(H1.2F3), H-2Kb (AF6-88.5), TCRb (H57-597), CD86 (GL1), CD90.2 (30-H12), Siglec F 
(E50-2440).  
 
Antibodies purchased from Thermo Fischer: CD5 (53-7.3), MHC Class II– I-A/I-E 
(M5/114.15.2), Ly6C (HK1.4).  
 
Antibodies purchased from eBioscience: CD25 (PC61.5), FOXP3 (NRRF-30), Ly6C 
(HK1.4). 
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Immunofluorescence 
Thymi were harvested and snap frozen in Optimal Cutting Temperature compound 
(Sakura Finetek). Tissue samples were sectioned into 7µm at -20ºC. Sections were then 
fixed and permeabilized in 100% acetone for 20 minutes at 4º C. Fixed sections were 
blocked with 5% bovine serum albumin (BSA) and Fc block (anti-CD16/CD32 (2.4G2, 
Tonbo Biosciences) for one hour at 20ºC. Antibodies were purchased from BD 
Biosciences: CD8a (53-6.7), CD11c (HL3), BioLegened: CD301b (MGL2; URA-1), and 
Vector Laboratories: Fluorescein labaled Ulex Europaeus Agglutinin I (UEAI). Sections 
were stained with an antibody cocktail in 0.5% BSA and 0.1% Tween-20 (Sigma Aldrich) 
overnight at 4º C. Following wash steps and DAPI staining, sections were mounted 
using Prolong anti-fade mounting medium (Life Technologies). Images were acquired 
using a Leica DM6000B epifluorescent microscope 16-72 hours later. 
 
Histo-cytometry 
Histo-cytometry was performed as previously described (134, 148). Briefly, fluorochrome 
intensities based on region of interest defined by DAPI staining were quantified and 
exported as .csv files using ImageJ. FlowJo version X (FlowJo LLC) was used for 
analysis.  
 
Statistical Analysis 
Statistical analyses were performed using Prism 8 (GraphPad). D’Agostino & Pearson 
test was used to assess normality. For comparison of two data sets, unpaired Student’s t 
test or unpaired Mann-Whitney test were performed (based on normality results). For 
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comparison of three or more data sets, ordinary one-way ANOVA with Holm-Sidak’s or 
Tukey’s multiple comparisons test was used. P-values less than 0.05 were considered 
significant. Sample size, experimental replicates, and additional details are provided in 
the figure legends.  
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Chapter 4 
 
 Conclusions 
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The immune system is balanced between self-antigen-driven tolerance and 
pathogen-driven immunity. Thymic selection of the T cell repertoire (central tolerance) 
and deletion and anergy in lymphoid and non-lymphoid organs (peripheral tolerance) 
serve as mechanisms to maintain this balance. The importance that central tolerance 
plays in upholding this balance is highlighted by the transcriptional regulator, AIRE. AIRE 
functions by promoting promiscuous gene expression of tissue restricted antigens by B 
cells and mTECs in the thymus in order to generate a T cell repertoire that is tolerant to 
peripheral organs (40, 85, 135). Mutations in AIRE result in APECED (autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy; also known as autoimmune 
polyendocrine syndrome type 1, APS1), which is characterized by autoantibody 
production and lymphocytic infiltration in multiple organs (155, 156). While the role of 
AIRE underscores the importance of the self-tolerance generated in the thymus, there 
are numerous APCs that coordinate to enact this process as well. Many studies gained 
insight into how central tolerance is directed within the thymus, however the use of 
different model systems obscured our understanding of how this occurs within the 
polyclonal thymocyte pool. The aim of this thesis work was to gain better insight into how 
central tolerance, particularly clonal deletion and Treg cell differentiation, is orchestrated 
within the polyclonal population. 
To better understand the developmental stages and corresponding anatomic 
locations at which thymocytes undergo clonal deletion within the polyclonal pool, we 
developed and validated a cleaved caspase-3 based assay to identify thymocytes 
undergoing clonal deletion. Because cleaved caspase-3 is expressed by all cells 
undergoing apoptosis, we utilized the activation markers, CD5 and TCRb, to distinguish 
between thymocytes undergoing death by neglect and clonal deletion. Using CCR7 to 
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approximate the anatomic location at which thymocytes were undergoing clonal deletion, 
we verified previous estimates that the majority of clonal deletion occurs within the 
thymus cortex (67, 68, 70). In contrast to seminal work which suggested that only the 
least mature thymocytes undergo clonal deletion (108), we found that developing 
thymocytes continue to undergo clonal deletion even at their most mature stages of 
development in the thymus medulla (Figure 4.1). This suggests a model by which not all 
self-reactive thymocytes encounter their deleting antigen before thymic egress and 
supports previous studies which propose that central tolerance is an imperfect process 
(42, 55, 56, 103). It is interesting to consider that the time developing thymocytes spend 
navigating the thymus prior to egress may correlate to the efficiency of central tolerance. 
For example, one might predict that mice treated with FTY720, a functional agonist of 
S1PR1 (Sphingosine-1-phosphate receptor 1), to temporarily prevent thymocyte egress 
would have a less autoreactive TCR repertoire compared to untreated animals. 
  
 
 
Figure 4.1. Model for susceptibility to clonal deletion during thymocyte 
maturation.  
 
Double positive (DP) thymocytes localized in the thymus cortex (C) undergo clonal deletion at the 
greatest frequency. Thymocytes continue to undergo clonal deletion in the medulla (M) at each 
stage of development (semi-mature (SM); mature 1 (M1); and mature 2 (M2)), but become less 
susceptible as they mature. 
 
  89 
We also examined how antigen presentation capability, namely MHC II and the 
co-stimulatory molecules, CD80 and CD86, impacted clonal deletion using this cleaved 
caspase-3 based assay. Our findings supported previous work that demonstrated a non-
redundant role for MHC II on bone marrow-derived APCs in mediating clonal deletion 
(45). Importantly, we also found that CD28-mediated co-stimulation, the significance of 
which had been controversial (119, 126–128, 157), is critical for clonal deletion in both 
the thymus cortex and medulla. We further established a non-redundant role for CD86 in 
mediating clonal deletion in the thymus cortex, suggesting that cortical thymocytes may 
be more sensitive to co-stimulation-driven clonal deletion than those in the medulla. 
Future work examining the dose-dependent effect of co-stimulatory molecule expression 
on thymocyte differentiation and clonal deletion will be necessary to support this 
hypothesis. 
We further explored these findings by more thoroughly examining the distinct 
APC subsets within the thymus. Given the different proportional representation, antigen-
presenting capabilities, and distinct functional properties of these various thymic APCs, 
we hypothesized that APCs may have non-redundant roles in mediating central 
tolerance. B cells and the two cDC subsets (XCR1+ cDC1 and SIRPa+ cDC2) were the 
most highly represented bone marrow-derived APCs within the thymus and also 
expressed the highest levels of MHC II and co-stimulatory molecules. Using mice with 
cell-specific deficiencies, we examined the relative role that these APCs play in 
generating nascent mTreg cells and mediating clonal deletion. 
Because nearly half of the mature Treg cells in the thymus are recirculating 
(110), we sought to identify makers to distinguish nascent from recirculating mTreg cells. 
We identified that CD73 in combination with CD44 could accurately identify both 
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recirculating mTreg and CD4 T cells. AIRE-deficient mice had a reduction in both 
nascent and recirculating mTreg cells, indicating that AIRE is critical to thymic mTreg cell 
differentiation. In contrast to previous studies that identified B cells as essential for 
mTreg cell development (86, 95), we found that nascent mTreg cell development in the 
absence of B cells was similar to WT mice. However, the recirculating mTreg cell pool 
was decreased in B cell-deficient animals, suggesting that previous findings may have 
been skewed by this recirculating population. 
Since there is currently no tool to efficiently target SIRPa+ cDC2, we sought an 
alternative method to deplete a substantial proportion of this population. We discovered 
that the thymus harbors a large fraction of CD301b-expressing SIRPa+ cDC2. The 
proportion of these CD301b+ SIRPa+ cDC2 was much greater than that in the skin 
draining lymph nodes, where this population was originally described. Further 
investigation of this population revealed that the type 2 cytokine enriched environment in 
the thymus was required for this population. Without IL-4 and IL-13 signaling, CD301b-
expressing SIRPa+ cDC2 were absent from the thymus. Because thymic tissue resident 
NKT2 are the major source of IL-4 in the thymus, we hypothesized that NKT cells are 
required for a major proportion of CD301b-expessing SIRPa+ cDC2. Indeed, the 
population of CD301b+ SIRPa+ cDC2 was reduced by half in the absence of NKT cells. 
Further enforcing the notion that the IL-4 produced by NKT2 cells supports this 
population, we determined that CD301b+ SIRPa+ cDC2 are localized primarily within the 
thymus medulla, where NKT2 are concentrated (Figure 4.2). 
Using the cleaved caspase-3 assay we developed to quantify clonal deletion at 
the population level, we assessed the relative contribution of different APC subsets to 
clonal deletion. As expected, AIRE-deficient animals had a reduction in medullary clonal 
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deletion events. Interestingly, depletion of CD301b-expessing SIRPa+ cDC2, also 
resulted in a modest reduction in medullary clonal deletion (Figure 4.2). We confirmed 
the findings of our cleaved caspase-3 assay by using tetramers to identify eGFP-specific 
CD4 T cells. Following immunization with eGFP peptide and CFA, we found that there 
were very few eGFP-specific CD4 T cells in MGL2DTR-eGFP mice compared to WT 
littermate controls. The total number of eGFP-specific CD4 T cells in MGL2DTR-eGFP was 
consistent with numbers proposed by Malhotra et al. that categorize clonal deletion as 
the major tolerance mechanism (42). 
 
 
Figure 4.2. CD301b+ SIRPa+ cDC2 mediate clonal deletion. 
 
CD301b+ SIRPa+ cDC2 require IL-4, produced by thymic resident NKT2 cells localized in the 
medulla, and IL-13, the source of which is currently unknown. Blue and purple shapes represent 
unique peptides induced by IL-4 and IL-13, including CD301b. These IL-4 and IL-13 dependent 
cDC2 mediate clonal deletion of medullary SP thymocytes in a non-redundant manner. 
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The studies outlined here implicate AIRE is the major enforcer of central 
tolerance, both by mTreg cell differentiation and clonal deletion, at the population level. 
A subset of type 2 cytokine-dependent SIRPa+ cDC2 were also critical for mediating 
clonal deletion. While we did not identify non-redundant roles for B cells, pDC, XCR1+ 
cDC1, or MNPs for mediating clonal deletion or mTreg cell selection, this does not rule 
out the possibility that these APC subsets facilitate central tolerance at the TCR 
repertoire level. To date, only XCR1+ cDC1 have been studied for their role in shaping 
the TCR repertoire, and the findings by two different groups remain controversial (45, 61, 
71, 80). Because XCR1+ cDC1 are well known to cross-present TRA acquired from 
mTEC (and therefore likely have overlapping peptidomes) (59–62), data that did not 
identify differences in Treg or CD8+ thymocyte repertoires suggested functional overlap 
between this cDC subset and mTEC in mediating central tolerance (71, 80). However, 
another group’s findings are more nuanced. Perry et al. demonstrated that XCR1+ cDC1 
affect both clonal deletion and Treg cell selection within the TCR repertoire (45, 61). This 
group showed that CD36, a scavenger receptor, mediates the transfer of AIRE-
dependent cell-surface (but not cytoplasmic) antigens to XCR1+ cDC1 (61). Through 
TCRa sequencing, this group showed that XCR1+ cDC1 facilitate Treg cell selection and 
clonal deletion and that they also contribute to a proportion of AIRE-dependent 
thymocyte selection. These findings support previous work that suggests a unique role 
for bone marrow-derived APC in mediating tolerance via indirect presentation (158). The 
different conclusions drawn by these two groups lies primarily within the analysis 
methods employed. In addition to the lack of consensus on data set analysis, other 
limitations exist; both groups restricted TCR diversity by using a transgenic fixed TCRb 
chain to facilitate data analysis (45, 80). It will be interesting to see how other APC 
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subsets impact development of the TCR repertoire once these complications are 
addressed. 
Although we did not examine the impact of distinct APCs on thymocyte selection 
at different ages, we did show that the proportion of APC subsets is different during 
neonatal development compared to adults. It is reasonable to hypothesize that the roles 
that these APC play in mediating clonal deletion or Treg cell selection would be unique 
in neonates compared to adults. In support of this hypothesis, it was recently shown that 
distinct Treg cell populations develop during the perinatal window and that these develop 
due to age-dependent differences in antigen processing in mTEC (49). 
Given that type 2 cytokines were essential for CD301b-expessing SIRPa+ cDC2, 
it is interesting to contemplate what other effects the type 2 cytokine-enriched 
environment of the thymus has on other thymic APC subsets. It also raises the question 
of whether the individual APC is more important for mediating tolerance or if a unique 
peptidome (in this case induced by IL-4 and IL-13) has an overall greater impact on the 
T cell repertoire selected. One might expect that IL-4Ra-deficient mice would have a 
more substantially altered TCR repertoire compared to mice lacking a specific APC 
subset. In addition to IL-4-producing NKT2, NKT1 and NKT17 effector populations also 
produce cytokines (IFN-g and IL-17 respectively) in the steady state (143). Additionally, 
IFN-b is produced by mTEC in the steady state and impacts T cell maturation in the 
thymus (109, 159, 160). Understanding how intrathymic cytokine production impacts 
APC antigen processing and presentation, the consequent peptidomes, and the resulting 
TCR repertoires will be the work of future studies.  
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